var title_f32_25_33168="Olopatadine: Drug information";
var content_f32_25_33168=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Olopatadine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32404?source=see_link\">",
"       Olopatadine (nasal): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/43/20147?source=see_link\">",
"       Olopatadine (ophthalmic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10177 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33168=[""].join("\n");
var outline_f32_25_33168=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32404?source=related_link\">",
"      Olopatadine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/43/20147?source=related_link\">",
"      Olopatadine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_25_33169="Isolating and positioning the vas during vasectomy";
var content_f32_25_33169=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Isolating and positioning the vas during vasectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The vas deferens is positioned to lie as superficially as possible. A \"three finger technique\" is used to manipulate the vas within the scrotum using the non-dominant hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clenney, TL, Higgins, JC. Vasectomy Techniques. American Family Physician 1999; 60:137. Copyright &copy;1999 Timothy Clenney, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33169=[""].join("\n");
var outline_f32_25_33169=null;
var title_f32_25_33170="Osteolytic metastases";
var content_f32_25_33170=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The vicious cycle of osteolytic metastasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 546px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tumor cells, in particular breast cancer, secrete parathyroid hormone related peptide (PTHrP)&nbsp;as the primary stimulator of osteoclastogenesis. In addition, tumor cells produce other factors that increase osteoclast formation including interleukin-6 (IL-6), prostaglandin E2 (PGE2), tumor necrosis factor (TNF), and macrophage colony-stimulating factor (M-CSF). These factors increase RANK ligand expression, which directly acts on osteoclast precursors to induce osteoclast formation and bone resorption. The bone resorption process releases factors such as transforming growth factor-beta (TGF-&beta;), which increase PTHrP production by tumor cells as well as growth factors (eg, insulin-like growth factors [IGFs],&nbsp;fibroblast growth factors [FGFs], platelet-derived growth factor [PDGF], bone morphogenetic proteins [BMPs])&nbsp;that increase tumor growth. This symbiotic relationship between bone destruction and tumor growth further increases bone destruction and tumor growth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from&nbsp;Roodman GD. Mechanisms of bone metastases. N Engl J Med 2004; 350:1655.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33170=[""].join("\n");
var outline_f32_25_33170=null;
var title_f32_25_33171="Human chorionic gonadotropin: Pediatric drug information";
var content_f32_25_33171=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Human chorionic gonadotropin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?25/60/26564?source=see_link\">",
"    see \"Human chorionic gonadotropin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/15/31988?source=see_link\">",
"    see \"Human chorionic gonadotropin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Novarel&reg;;",
"     </li>",
"     <li>",
"      Pregnyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F151100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chorionic Gonadotropin for Injection;",
"     </li>",
"     <li>",
"      Pregnyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gonadotropin",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ovulation Stimulator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/60/26564?source=see_link\">",
"      see \"Human chorionic gonadotropin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children: I.M. (many regimens have been described):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prepubertal cryptorchidism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1000-2000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose 3 times/week for 3 weeks or 4000 units 3 times/week for 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5000 units every second day for 4 injections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     500 units 3 times/week for 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypogonadotropic hypogonadism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     500-1000 units 3 times/week for 3 weeks, followed by the same dose twice weekly for 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1000-2000 units 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4000 units 3 times/week for 6-9 months; reduce dosage to 2000 units 3 times/week for additional 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Induction of ovulation: Females: 5000-10,000 units the day following the last dose of menotropins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spermatogenesis induction associated with hypogonadotropic hypogonadism: Male: Treatment regimens vary (range: 1000-2000 units 2-3 times a week). Administer hCG until serum testosterone levels are normal (may require 2-3 months of therapy), then may add follitropin alfa or menopausal gonadotropin if needed to induce spermatogenesis; continue hCG at the dose required to maintain testosterone levels.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F151085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 10,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Novarel&reg;: 10,000 units [contains benzyl alcohol (in diluent)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnyl&reg;: 10,000 units [contains benzyl alcohol (in diluent)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F151072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Administer I.M. only",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following reconstitution with provided diluent, stable for 30-90 days (depending upon preparation) when stored at 2&deg;C to 15&deg;C",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypogonadotropic hypogonadism, prepubertal cryptorchidism; induce ovulation and pregnancy in anovulatory, infertile women",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F151119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, fatigue, headache, irritability, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia, precocious puberty",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction, pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reaction (local or systemic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Arterial thrombus, ovarian cyst rupture, ovarian hyperstimulation syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chorionic gonadotropin or any component; precocious puberty, prostatic carcinoma or other androgen-dependent neoplasms; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with asthma, seizure disorders, migraine, cardiac or renal disease; may induce precocious puberty in children being treated for cryptorchidism; discontinue if signs of precocious puberty occur; safety and efficacy in children &lt;4 years of age has not been established",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     hCG is",
"     <b>",
"      not",
"     </b>",
"     effective in the treatment of obesity. hCG should only be used by clinicians who are experienced in the management of fertility disorders. May cause ovarian hyperstimulation syndrome (OHSS); if severe, treatment should be discontinued and patient should be hospitalized. OHSS results in a rapid (&lt;24 hours to 7 days) accumulation of fluid in the peritoneal cavity, thorax, and possibly, the pericardium, which may become more severe if pregnancy occurs; monitor for ovarian enlargement. Use may lead to multiple births, arterial thromboembolism, enlargement or rupture of pre-existing ovarian cysts with resultant hemoperitoneum.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pregnyl&reg; contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of Pregnyl&reg; in neonates.",
"     <i>",
"      In vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F151080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F151082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2998838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Teratogenic effects (forelimb, CNS) have been noted in animal studies at doses intended to induce superovulation (used in combination with gonadotropin). Testicular tumors in otherwise healthy men have been reported when treating secondary infertility.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3335393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Male: Serum testosterone levels, semen analysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Female: Ultrasound and/or estradiol levels to assess follicle development; ultrasound to assess number and size of follicles; ovulation (basal body temperature, serum progestin level, menstruation, sonography)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1057328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depends on application and methodology; &lt;3 milli international units/mL (SI: &lt;3 units/L) usually normal (nonpregnant)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates production of gonadal steroid hormones by causing production of androgen by the testis; as a substitute for luteinizing hormone (LH) to stimulate ovulation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes mainly into the testes in males and into the ovaries in females",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, biphasic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terminal: 23 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Approximately 10% to 12% excreted unchanged in urine within 24 hours; detectable amounts may continue to be excreted in the urine for up to 3-4 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13392 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33171=[""].join("\n");
var outline_f32_25_33171=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151099\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151100\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057326\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057322\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151085\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151072\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057330\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057324\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057329\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151119\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057333\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057321\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057320\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299037\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151080\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151082\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2998838\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335393\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057328\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057319\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057332\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13392\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13392|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/60/26564?source=related_link\">",
"      Human chorionic gonadotropin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/15/31988?source=related_link\">",
"      Human chorionic gonadotropin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_25_33172="Colchicine and probenecid: Patient drug information";
var content_f32_25_33172=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Colchicine and probenecid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/61/36821?source=see_link\">",
"     see \"Colchicine and probenecid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop gouty arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701857",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to colchicine, probenecid, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698459",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked if you are on this drug for a long time. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain, belly pain, or blood in the urine. May be signs of a kidney stone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to take this drug as you have been told by your doctor. Do not use more than you were told to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11707 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-877DD6BC00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33172=[""].join("\n");
var outline_f32_25_33172=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021704\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021706\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021705\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021710\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021711\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021713\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021708\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021709\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021714\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021715\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/61/36821?source=related_link\">",
"      Colchicine and probenecid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_25_33173="Pemphigus vulgaris biopsy";
var content_f32_25_33173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic specimen of a bullous lesion in a patient with pemphigus vulgaris demonstrates the characteristic loss of cohesion between epidermal cells (acantholysis) with an intact basement membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33173=[""].join("\n");
var outline_f32_25_33173=null;
var title_f32_25_33174="Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations";
var content_f32_25_33174=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/25/33174/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33174/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/25/33174/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33174/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/25/33174/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33174/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/25/33174/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute renal failure interferes with the excretion of water, electrolytes, and organic solutes (such as urea, creatinine, and uric acid). A few simple calculations will permit us to understand the limits on these processes and how they may be affected by dialytic procedures. The normal glomerular filtration rate is approximately 170 to 180",
"    <span class=\"nowrap\">",
"     L/day,",
"    </span>",
"    which is roughly the clearance of those solutes like creatinine that are excreted primarily by glomerular filtration.",
"   </p>",
"   <p>",
"    Most patients with acute renal failure tolerate the solute retention that accompanies a glomerular filtration rate that is 10 percent of normal (17",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    or 12",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This is therefore a reasonable initial target among patients who are not hypercatabolic. In comparison, hypercatabolic patients require more aggressive solute removal techniques to maintain acceptable or optimal steady-state or time-averaged concentrations of solutes.",
"   </p>",
"   <p>",
"    The mechanisms of solute removal by dialysis and the hemodynamic changes that occur will be reviewed here. The indications for dialysis in patients with acute renal failure, the goals for dialysis delivery, concerns related to whether dialysis delays the recovery of renal function, and the effects of different hemodialysis membranes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF SOLUTE REMOVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of solute removal during dialysis can occur by two different mechanisms:",
"    <strong>",
"     passive diffusion",
"    </strong>",
"    down a favorable concentration gradient from the plasma into the dialysis fluid; and during the ultrafiltration (or",
"    <strong>",
"     convection",
"    </strong>",
"    ) of plasma water across the membrane of the hemofilter. The frictional forces between water and solutes (called",
"    <strong>",
"     solvent drag",
"    </strong>",
"    ) results in the convective transport of small and middle molecular weight solutes (less than 5000 daltons) in the same direction.",
"   </p>",
"   <p>",
"    The dialytic clearance of a solute is dependent in part upon size, with larger molecules (including those that are protein bound) being less efficiently removed. The sieving coefficient (SC) is a measure of a solute's filterability during ultrafiltration, being equal to the ratio of the solute concentration in the filtrate to that in the arterial plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/4\">",
"     4",
"    </a>",
"    ]. The SC ranges from zero for a solute that is completely rejected to one for a solute that is freely filtered (such as urea and creatinine). The total clearance of a solute during ultrafiltration is equal to the product of the SC and the rate of fluid removal (the ultrafiltration rate). For a solute with an SC of one, the concentration of the solute in the filtrate is roughly the same as that in the plasma and the solute clearance by filtration is",
"    <strong>",
"     equal",
"    </strong>",
"    to the net ultrafiltration rate. A more detailed discussion of these concepts can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/16/27909?source=see_link\">",
"     \"Drug removal during continuous renal replacement therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With some continuous renal replacement therapies (CRRTs), such as continuous arteriovenous or venovenous hemofiltration, all solute removal occurs by convection since there is no exposure to dialysis fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=see_link\">",
"     \"Continuous renal replacement therapies: Overview\"",
"    </a>",
"    .) If, as noted above, the aim is a clearance rate of 17",
"    <span class=\"nowrap\">",
"     L/day,",
"    </span>",
"    then the ultrafiltration rate for freely filtered small solutes such as urea must be at least equal to this level to achieve the desired rate of solute removal. Ultrafiltration rates above this level may result in a greater degree of total urea removal than achieved with conventional intermittent hemodialysis; urea clearance per unit time is much greater with conventional hemodialysis, but this effect is counteracted by the much shorter duration of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/6\">",
"     6",
"    </a>",
"    ]. Although loss of ultrafiltrate with the same concentration as the plasma will not directly lower the BUN or plasma creatinine concentration, the administration of replacement fluid to prevent volume depletion will do so by dilution.",
"   </p>",
"   <p>",
"    In general, the clearance of a small solute with an SC of one cannot exceed the ultrafiltration rate with these procedures (",
"    <a class=\"graphic graphic_table graphicRef65154 \" href=\"mobipreview.htm?3/26/3501\">",
"     table 1",
"    </a>",
"    ). This limitation can be modestly exceeded by about 15 percent if the replacement fluid is administered before the filter (called",
"    <strong>",
"     predilution",
"    </strong>",
"    ). This will acutely lower the BUN, allowing some of the intracellular urea in red cells to diffuse out into the plasma and be removed in the filter.",
"   </p>",
"   <p>",
"    Solute removal is substantially faster (over 160",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    for urea) with standard hemodialysis in which small solutes passively diffuse from the plasma into the dialysis fluid down a favorable concentration gradient. Blood and dialysate move at high rates in a countercurrent fashion through the dialyzer. The constant resupply of new blood with a high solute concentration and new dialysate with a low solute concentration maximizes the rate of diffusive loss by maintaining a high concentration gradient between the two compartments. The net effect is that the loss of small solutes is much greater than that of water.",
"   </p>",
"   <p>",
"    Standard hemodialysis can also be used to remove fluid by increasing the transmembrane pressure gradient. As a result, it is the dialytic modality of choice in stable patients with severe acute renal failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    .) However, hemodialysis (for either acute or chronic renal failure) is frequently associated with episodes of hypotension, making it less useful in hypotensive or hemodynamically unstable patients. It is in this setting that CRRT has an advantage, since the risk of hypotension is much lower.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISMS OF HEMODIALYSIS-INDUCED HYPOTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of how hemodialysis causes hypotension allows us to appreciate the advantages of CRRT. The major determinants of hemodynamic stability are the rate of fluid removal",
"    <strong>",
"     and",
"    </strong>",
"    the rate of solute removal. It had been assumed that the primary cause of intradialytic hypotension was induction or exacerbation of intravascular volume depletion by rapid ultrafiltration. This simplistic hypothesis was disproved by the observation by Bergstrom that patients who became hypotensive during hemodialysis tolerated the same degree and rate of fluid removal with pure hemofiltration in which there was",
"    <strong>",
"     no diffusive component",
"    </strong>",
"    of solute loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proposed explanation for this phenomenon is illustrated in Figures 2 and 3. During conventional hemodialysis, the rapid diffusive removal of urea (and other small solutes) results in a reduction in the plasma osmolality, which is now less than that in the cells (",
"    <a class=\"graphic graphic_figure graphicRef53752 \" href=\"mobipreview.htm?3/31/3582\">",
"     figure 1",
"    </a>",
"    ). As a result, water moves osmotically into the cells, further depleting the extracellular volume which has also been diminished by ultrafiltration. It is also possible that the rapid fall in plasma osmolality itself contributes to the hemodynamic instability, perhaps by interfering with sympathetic responsiveness to volume depletion (see below).",
"   </p>",
"   <p>",
"    Urea has been a biomarker solute whose removal has been a part of the definition of dialysis efficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/8\">",
"     8",
"    </a>",
"    ]. Although urea is generally considered to be an \"ineffective osmole\" because it can cross cell membranes, this process requires several hours to reach equilibrium. Thus, urea acts as an effective osmole that can induce water shifts in the setting of acute dialysis. In addition to promoting the development of hypotension, these water shifts can also induce cerebral edema and the neurologic symptoms of the dialysis disequilibrium syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13125?source=see_link\">",
"     \"Dialysis disequilibrium syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison to hemodialysis, the fluid removed via isolated ultrafiltration has the same concentration of small solutes as the plasma. As a result, no osmotic gradient is created between the cells and the extracellular fluid, and water movement into the cells does not occur. To the contrary, the fall in intravascular volume will raise the plasma protein concentration and therefore the plasma oncotic pressure. This will draw water from the extracellular space and the cells into the vascular space, thereby leading to the relative preservation of intravascular volume (",
"    <a class=\"graphic graphic_figure graphicRef76802 \" href=\"mobipreview.htm?3/4/3150\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The etiologic importance of osmolar changes in dialysis-related hypotension has been confirmed by other investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In addition, a number of observations have confirmed each of the proposed steps in Bergstrom's hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intracellular fluid volume increases during conventional hemodialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Water moves from the extracellular fluid into the cells with hemodialysis but in the opposite direction during hemofiltration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even when diffusive solute loss is allowed to occur during CRRT (by running dialysate on the other side of the dialysis membrane), hypotension is less likely because of the much slower rate of urea removal. The urea clearance during CAVHD, for example, is approximately 17",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    depending on the operating conditions, as compared to values above 160",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    with conventional hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=see_link\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37303?source=see_link\">",
"     \"Continuous arteriovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hemodynamics of hemofiltration and hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The net effect is that arterial blood pressure and systemic vascular resistance are usually maintained or even increased during hemofiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. In comparison, both of these parameters tend to fall when a similar volume of fluid is removed by hemodialysis. In addition to the osmotic shifts, patients treated with hemodialysis tend to have more severe derangements in autonomic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/14,15,17\">",
"     14,15,17",
"    </a>",
"    ]. How this occurs is not known, but venous vasoconstriction (which increases venous return to the heart) is an important mechanism to support cardiovascular stability during hemofiltration and may be impaired during hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/16,18,19\">",
"     16,18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/14/19684?source=see_link\">",
"     \"Autonomic dysfunction in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of myocardial stunning in chronic hemodialysis is common but poorly understood at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/20\">",
"     20",
"    </a>",
"    ]. Whether such a result is present in hemofiltration is yet unknown.",
"   </p>",
"   <p>",
"    Vasoconstriction due to lower temperatures with hemofiltration also may contribute to the difference in vascular reactivity between hemodialysis and hemofiltration. The role of temperature was addressed in a crossover study in which hemodynamic measurements were determined in 11 patients who underwent cold hemofiltration, warm hemofiltration, and combined ultrafiltration and hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/20\">",
"     20",
"    </a>",
"    ]. When care was taken to insure that hemofiltration and combined therapy were performed at equivalent warm temperatures, no difference in blood pressure or reactivity was observed between the two modalities. By comparison, cold hemofiltration was associated with significant increases in blood pressure and vascular resistance when compared with warm hemofiltration and combined therapy.",
"   </p>",
"   <p>",
"    CRRT may also protect systemic hemodynamics by a similar mechanism. The high rate of fluid removal (which can exceed 500",
"    <span class=\"nowrap\">",
"     mL/h)",
"    </span>",
"    may require the administration of a substitution fluid. When given unwarmed (ie, at room temperature), the ensuing cooling of the patient can lead to cutaneous vasoconstriction and preservation of the central blood volume and blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24690?source=see_link\">",
"     \"Cool temperature hemodialysis: Hemodynamic effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It must be emphasized, however, that the protection afforded by hemofiltration is",
"    <strong>",
"     relative",
"    </strong>",
"    , not absolute. Hypotension can still occur if too much fluid is removed or if fluid is removed too rapidly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other factors can also contribute to hemodialysis-induced hypotension in selected patients. These include bleeding induced by the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    given to prevent clotting in the dialyzer, the use of acetate rather than bicarbonate as the dialysate buffer (now a rare problem), certain medications, underlying heart disease, and, in relatively healthy patients, food ingestion during dialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Type of dialysis membrane",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of dialysis membrane used may be an additional factor that can affect hemodynamic stability. There is evidence in some, but not all studies, that hemofiltration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    continuous dialysis with very porous membranes may be beneficial by removing middle to large molecules with cardiodepressant, vasodilatory, or immunomodulatory properties that cannot easily cross conventional dialysis membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33174/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. Complement activating membranes can initiate an inflammatory process that contributes to vasodilation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=see_link\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .) An additional hemodynamic benefit of porous biocompatible membranes may be to enhance the rate of recovery of renal function and to improve patient outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    .) Thus, the minimal extra cost of these membranes appears to be justified by the potential benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H554976036\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The process of solute removal during hemodialysis can occur by two different mechanisms: passive diffusion&nbsp;down a favorable concentration gradient from the plasma into the dialysis fluid; and during the ultrafiltration (or convection) of plasma water across the membrane of the hemofilter. With some continuous renal replacement therapies (CRRTs), such as continuous arteriovenous or venovenous hemofiltration, all solute removal occurs by convection since there is no exposure to dialysis fluid. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of solute removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major determinants of hemodynamic stability during renal replacement therapy are the rates of fluid and solute removal. During conventional hemodialysis, the rapid diffusive removal of solutes results in a reduction in the plasma osmolality, thereby causing water to move osmotically into the cells. In combination with ultrafiltration, this further depletes the extracellular volume and, together, lowers the systemic blood pressure. By comparison, the fluid removed via isolated ultrafiltration has the same concentration of small solutes as plasma. The relative preservation of intravascular volume will occur since there is no osmotic gradient to draw water movement into the cells. With CRRT, hypotension is also less likely because of the much lower rate of urea removal. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanisms of hemodialysis-induced hypotension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given solute and fluid removal considerations, the arterial blood pressure and systemic vascular resistance are usually maintained or even increased during hemofiltration. By comparison, both the blood pressure and vascular resistance tend to fall when a similar fluid of fluid is removed by hemodialysis. However, the protection afforded by hemofiltration is only relative since hypotension still occurs if too much fluid is removed or if fluid is removed too rapidly. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hemodynamics of hemofiltration and hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/1\">",
"      Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/2\">",
"      VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/3\">",
"      RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/4\">",
"      Colton CK, Henderson LW, Ford CA, Lysaght MJ. Kinetics of hemodiafiltration. I. In vitro transport characteristics of a hollow-fiber blood ultrafilter. J Lab Clin Med 1975; 85:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/5\">",
"      Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis 1998; 32:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/6\">",
"      Clark WR, Mueller BA, Alaka KJ, Macias WL. A comparison of metabolic control by continuous and intermittent therapies in acute renal failure. J Am Soc Nephrol 1994; 4:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/7\">",
"      Bergstrom, J, Asaba, H, Furst, P, Oules, R. Dialysis, ultrafiltration, and blood pressure. Proc Eur Dial Transplant Assoc 1976; 13:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/8\">",
"      Rucker D, Thadhani R, Tonelli M. Trace element status in hemodialysis patients. Semin Dial 2010; 23:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/9\">",
"      Henrich WL, Woodard TD, Blachley JD, et al. Role of osmolality in blood pressure stability after dialysis and ultrafiltration. Kidney Int 1980; 18:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/10\">",
"      Swartz RD, Somermeyer MG, Hsu CH. Preservation of plasma volume during hemodialysis depends on dialysate osmolality. Am J Nephrol 1982; 2:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/11\">",
"      Kimura G, Irie A, Kuroda K, et al. Absence of transcellular fluid shift during haemofiltration. Proc Eur Dial Transplant Assoc 1980; 17:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/12\">",
"      Schuenemann B, Borghardt J, Falda Z, et al. Reactions of blood pressure and body spaces to hemofiltration treatment. Trans Am Soc Artif Intern Organs 1978; 24:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/13\">",
"      Wehle B, Asaba H, Castenfors J, et al. Hemodynamic changes during sequential ultrafiltration and dialysis. Kidney Int 1979; 15:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/14\">",
"      Quellhorst E, Schuenemann B, Hildebrand U, Falda Z. Response of the vascular system to different modifications of haemofiltration and haemodialysis. Proc Eur Dial Transplant Assoc 1980; 17:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/15\">",
"      Baldamus CA, Ernst W, Frei U, Koch KM. Sympathetic and hemodynamic response to volume removal during different forms of renal replacement therapy. Nephron 1982; 31:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/16\">",
"      Paganini EP, Fouad F, Tarazi RC, et al. Hemodynamics of isolated ultrafiltration in chronic hemodialysis patients. Trans Am Soc Artif Intern Organs 1979; 25:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/17\">",
"      Zucchelli P, Santoro A, Sturani A, et al. Effects of hemodialysis and hemofiltration on the autonomic control of circulation. Trans Am Soc Artif Intern Organs 1984; 30:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/18\">",
"      Chen WT, Chaignon M, Omvik P, et al. Hemodynamic studies in chronic hemodialysis patients with hemofiltration/ultrafiltration. Trans Am Soc Artif Intern Organs 1978; 24:682.",
"     </a>",
"    </li>",
"    <li>",
"     Kooman, JP. The role of the venous system in the regulation of hemodynamics during hemodialysis (Thesis). Universitaire Pers, Maastricht, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/20\">",
"      van Kuijk WH, Hillion D, Savoiu C, Leunissen KM. Critical role of the extracorporeal blood temperature in the hemodynamic response during hemofiltration. J Am Soc Nephrol 1997; 8:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/21\">",
"      Hoffmann JN, Hartl WH, Deppisch R, et al. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int 1995; 48:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/22\">",
"      Grootendorst AF, van Bommel EF, van der Hoven B, et al. High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig. Intensive Care Med 1992; 18:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/23\">",
"      Stein B, Pfenninger E, Gr&uuml;nert A, et al. Influence of continuous haemofiltration on haemodynamics and central blood volume in experimental endotoxic shock. Intensive Care Med 1990; 16:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/24\">",
"      Stein B, Pfenninger E, Gr&uuml;nert A, et al. The consequences of continuous haemofiltration on lung mechanics and extravascular lung water in a porcine endotoxic shock model. Intensive Care Med 1991; 17:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33174/abstract/25\">",
"      Sander A, Armbruster W, Sander B, et al. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med 1997; 23:878.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1852 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-906C751B57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33174=[""].join("\n");
var outline_f32_25_33174=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H554976036\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF SOLUTE REMOVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISMS OF HEMODIALYSIS-INDUCED HYPOTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hemodynamics of hemofiltration and hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Type of dialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H554976036\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1852\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1852|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/31/3582\" title=\"figure 1\">",
"      Water shifts in hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/4/3150\" title=\"figure 2\">",
"      Water shifts hemofiltration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1852|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/26/3501\" title=\"table 1\">",
"      Solute clearance in HD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/14/19684?source=related_link\">",
"      Autonomic dysfunction in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37303?source=related_link\">",
"      Continuous arteriovenous hemodialysis: Technical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=related_link\">",
"      Continuous renal replacement therapies: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24690?source=related_link\">",
"      Cool temperature hemodialysis: Hemodynamic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13125?source=related_link\">",
"      Dialysis disequilibrium syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/16/27909?source=related_link\">",
"      Drug removal during continuous renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_25_33175="Allergen sampling in the environment";
var content_f32_25_33175=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Allergen sampling in the environment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/25/33175/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33175/contributors\">",
"     Robert G Hamilton, PhD, DABMLI, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/25/33175/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33175/contributors\">",
"     Peter S Creticos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/25/33175/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33175/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/25/33175/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6881103\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance of allergens remains a cornerstone in the management of patients with allergic diseases. However, many allergens, such as those associated with dust mites and animal danders, are ubiquitous in the environment, and cannot be entirely avoided. Therefore, effective avoidance measures should be tailored to the specific allergens that are important for a particular patient. The clinician should also focus on environments that can be altered (ie, indoor spaces) and those in which the patient spends significant time. In this context, allergen sampling of the environment may be clinically useful.",
"   </p>",
"   <p>",
"    This topic will discuss the identification of allergens, indications for allergen sampling, and methods for sampling and measuring allergens, with a focus on the indoor environment. Indicators of quality testing methods that the clinician can use to identify an appropriate testing laboratory are also discussed. Testing of individuals to determine sensitivity to specific allergens, and measures to reduce indoor allergen exposure are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881110\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF ALLERGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An allergen is a natural substance that is generally innocuous to most people, but when introduced into a genetically predisposed individual, elicits the formation of IgE antibodies specific to that substance. These allergen-specific IgE antibodies coat the individual&rsquo;s mast cells and basophils. When the subject is reexposed to the allergen, the specific IgE antibodies bind to the allergen and activate these cells, resulting in the release of an array of inflammatory mediators that precipitate the symptoms of allergic disease.",
"   </p>",
"   <p>",
"    The identification of clinically important allergens begins by obtaining clinical histories from affected individuals who, when exposed to a given substance, develop similar signs and symptoms that are known to represent IgE-mediated allergic disease. Making the connection between symptoms and a specific exposure is most straightforward when allergic symptoms appear shortly after exposure (eg, anaphylaxis following ingestion of peanuts, severe rhinitis or asthma following grass cutting). In contrast, allergens to which people are chronically exposed are much more difficult to identify. As an example, it took several decades to identify dust mite as the primary source of allergenic material in house dust [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, the magnitude and type of the symptoms may vary as a function of allergen dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/2\">",
"     2",
"    </a>",
"    ]. Route of exposure also affects the clinical presentation. Allergens that are inhaled or injected usually cause more immediate symptoms compared with those that are ingested.",
"   </p>",
"   <p>",
"    Once the association between symptoms and a specific exposure is made, blood is collected from these individuals and serum containing allergen-specific IgE is used in subsequent analysis. In some cases, the suspect material can be used in its naturally occurring form to skin test the patient.",
"   </p>",
"   <p>",
"    To determine what component(s) of the suspect allergenic material is acting as the allergen, a bulk quantity of the substance is collected and solubilized, usually by soaking it in a physiologic saline solution. Although seemingly crude, this simple technique mimics the conditions that are present when the material contacts a mucous membrane. The resulting solution generally contains a complex mixture of proteins, carbohydrates, and lipids, which can be analyzed using a number of physical, chemical and immunological laboratory techniques. Most (not all) allergens are proteins or contain proteins. Protein components are separated based upon their size or net charge. Some can be immobilized on paper for detection by IgE antibodies from the symptomatic patient(s) using Western blotting or isoelectric focusing immunoblotting.",
"   </p>",
"   <p>",
"    Sera from symptomatic patients are then applied to the blots to determine which components bind IgE. This process results in identification of allergens based upon molecular weight",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    isoelectric point. Protein sequencing may be performed to get the precise primary structure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/3\">",
"     3",
"    </a>",
"    ]. The processes used in the production of allergens for diagnostic testing and treatment are similar and are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15127?source=see_link&amp;anchor=H2#H2\">",
"     \"An overview of allergen extracts\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another technique for screening for novel allergens within a known allergenic substance involves creating a cDNA library from the substance, which is then screened with serum IgE antibodies from a population of people allergic to the substance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/4\">",
"     4",
"    </a>",
"    ]. Verification of allergenicity then requires expression of the suspected allergen (eg, in E. coli) and confirmation of allergenicity by in vitro activation of effector cells (eg, basophils) from individuals who are known to manifest objective allergic symptoms following a challenge with the substance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4414763\">",
"    <span class=\"h2\">",
"     Determining the importance of an allergen within a population",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall importance of a given allergen within a population of allergic patients is determined by the percentage of individuals who produce IgE antibody against it. These determinations are made using study groups of patients who are allergic to given allergen source (eg, cats). To be designated as a &ldquo;major&rdquo; allergen, over 50 percent of subjects who are sensitized to the source need to have IgE antibodies that detect that specific allergen. As an example, feline uteroglobin (Fel d 1) is the major allergen in cat dander, and is detected by IgE in the sera of 60 to 90+ percent of cat-allergic patients, depending on whether cat allergen extract or recombinant Fel d 1 is used as the allergen source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians and patients sometimes wonder if an important indoor or outdoor allergen could have been overlooked. The approach described above should detect the majority of clinically relevant allergens provided the following requirements are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The environmental sample collected needs to be representative of all relevant environments in which the exposure is occurring, and it needs to contain the allergens of interest",
"     </li>",
"     <li>",
"      The method of allergen extraction should mimic how the allergenic material normally contacts the human body (eg, isotonic extraction of aeroallergens typically absorbed into mucosa of the lung or an acidic solvent extraction that resembles gastric fluid to accurately identify allergens that are absorbed in the stomach after ingestion)",
"     </li>",
"     <li>",
"      The analytical method (eg, Western blot analysis) used to identify proteins that bind IgE needs to be accurate and able to discriminate components based on their size or charge",
"     </li>",
"     <li>",
"      The individual serum or pooled sera used to probe the extracted allergen needs to be collected from a population of patients who have unequivocal symptoms to the allergen source being investigated",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4414676\">",
"    <span class=\"h2\">",
"     Identifying the relevance of an allergen to a specific patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for the presence of IgE antibodies against various allergens is part of the diagnosis of allergic rhinitis, allergic asthma, and several other allergic disorders. Following a detailed clinical history and physical examination, tests for allergen-specific IgE are performed. These usually consist of in vivo skin tests or provocation tests or in vitro immunoassays based on ELISA technology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients who have demonstrable IgE to a specific allergen are said to be sensitized to that allergen. The diagnosis of various allergic diseases is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnostic evaluation of food allergy\", section on 'In vitro testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3882220\">",
"    <span class=\"h2\">",
"     Identifying novel allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;New allergens emerge periodically. In some cases, the source is relatively obvious, such as the Asian ladybug (Harmonia axyridis), which has become prominent in the United States in recent years. This insect can infest homes and buildings during cool weather and can trigger rhinitis and asthma in certain individuals. The link between infestation and allergic symptoms was apparent to both patients and clinicians.",
"   </p>",
"   <p>",
"    Allergens that are not visible or intuitively obvious may only be revealed by a lengthy investigative process involving epidemiologists and laboratory immunologists. The emergence of latex allergy in the early 1990s illustrates this process. At the time, natural rubber latex (Hevea brasiliensis) was used in gloves, catheters, and other medical items and was not known to be an allergenic material. Anaphylaxis was reported in six patients at one institution following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema examinations, one of whom died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/6\">",
"     6",
"    </a>",
"    ]. Initially, barium was thought to be the culprit; however, careful investigation of materials from various items used in the implicated procedures revealed that proteins from latex catheters, gloves, and raw latex could bind IgE antibody in serum from affected patients. One patient volunteered to be skin tested to extracts of the latex products and demonstrated immediate positive results, further confirming latex as the cause. It took many years before all of the principal latex allergens were identified. Products containing natural rubber latex are now known to contain at least 13 potent allergenic proteins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=see_link\">",
"     \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40070?source=see_link\">",
"     \"Latex allergy: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881117\">",
"    <span class=\"h1\">",
"     SOURCES OF AEROALLERGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal outdoor aeroallergens are pollens released from grasses, trees, and weeds, as well as outdoor molds. The main indoor aeroallergens are released from dust mites, fur-bearing animals, and insects (eg, cockroaches). The table contains a summary of the major categories of known allergens (",
"    <a class=\"graphic graphic_table graphicRef80043 \" href=\"mobipreview.htm?35/27/36283\">",
"     table 1",
"    </a>",
"    ). Allergens are also found in drugs, venoms, foods, parasites, and a variety of occupational materials, although these are not discussed here. Assessing mold in the environment and the controversies that surround the role of molds in human disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/54/11110?source=see_link\">",
"     \"Assessment of mold in the indoor environment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25689?source=see_link\">",
"     \"The role of fungi (molds) in human disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881124\">",
"    <span class=\"h2\">",
"     Outdoor aeroallergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence and relative level of various pollens in outdoor air is determined by a network of pollen counting stations dispersed around the United States, usually in or near major cities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/7\">",
"     7",
"    </a>",
"    ]. Typically, a cascade or suction impactor device (rotarod or Burkard sampler) is used to sample the air at daily or weekly intervals. Technical limitations of these methods include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &rdquo;Pollen counts&rdquo; are retrospective and represent an integrated measure of pollen in the air over the previous 24 hours. However, by the time a pollen count is tabulated and reported, the actual pollen content in the air may have changed significantly, because levels of each pollen type are highly dependent on weather conditions and can fluctuate dramatically in short periods of time.",
"     </li>",
"     <li>",
"      Routine pollen counts are variable in their specificity. The standards defined by the National Allergy Bureau (Aeroallergen Network of the American Academy of Allergy, Asthma, and Immunology) requests that a center report actual raw numbers for major categories of aeroallergens, or report levels as",
"      <span class=\"nowrap\">",
"       low/medium/high.",
"      </span>",
"      As an example, if an overall level for all pollens is the only information provided, without individual analyses of tree, grass, and weed pollens, then the information may be misleading for some allergic patients. On a day when grass pollen is high and pollen counts are reported as &ldquo;high,&rdquo; a person sensitized to ragweed may be minimally symptomatic and may be confused by the report of high counts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881131\">",
"    <span class=\"h2\">",
"     Indoor aeroallergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal indoor allergens that induce upper and lower airway allergic symptoms are released by dust mites, fur-bearing pets and rodents, insects (eg, cockroaches and Asian lady bugs), and molds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, pollen and outdoor animal allergens and molds can be transported into the home to varying degrees. For each type of allergen, there are indicator allergens (usually the major allergen) that can be measured in house dust samples. The level of these indicator allergens can be used to identify an environment that places a sensitized individual at risk for upper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower airway allergic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allergen levels can be influenced by many factors, including the building structure; the type of heating and cooling systems; the season, temperature and humidity; pets in and around the environment; furniture and carpeting; and the number of residents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881138\">",
"    <span class=\"h3\">",
"     Dust mites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;house dust mite&rdquo; refers to four species of arachnid mites that commonly populate homes: Dermatophagoides (D.) pteronyssinus, D. farinae, D. microceras, and Euroglyphus maynei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/1\">",
"     1",
"    </a>",
"    ]. Dust mites live and breed in mattresses, carpets and upholstered furniture, where they absorb water from the air and eat skin and dander shed from humans and animals. Fecal pellets and decaying body parts from these mites contain potent allergens, such as group 1 and 2 allergens from D. pteronyssinus (Der p 1 and 2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/10\">",
"     10",
"    </a>",
"    ]. A third major allergen, Der p 23, was identified in 2013. Der p 23 is a protein found in the lining of the midgut of D. pteronyssinus, as well as on the surface of fecal pellets, which can become airborne upon excretion and was recognized by IgE antibodies from 74 percent of dust mite allergic patients in one large study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881145\">",
"    <span class=\"h3\">",
"     Fur-bearing animals",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of domesticated animals including cats, dogs, guinea pigs, hamsters, rabbits, rats, and mice produce dander, saliva, and urine that contain allergens.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The domestic cat (Felis domesticus) releases a potent allergen (Fel d 1) from its sublingual mucous salivary glands and hair root sebaceous glands [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/11\">",
"       11",
"      </a>",
"      ]. Fel d 1 adheres to fibers in carpets and upholstered furniture and to respirable dust particles from 2 to 10 microns in size. Levels of Fel d 1 are used as an indicator of cat allergen burden in house dust. Even pet-free homes and classroom environments have low basal levels of cat and dog allergens, as the allergens are transported into the area on the clothing of people who have household pets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The domesticated dog (Canis familiaris) also releases allergenic proteins from its hair and dander [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/13\">",
"       13",
"      </a>",
"      ]. While both common and breed specific dog allergens have been reported, Can f 1, is the major cross-reactive dog allergen that is used as an indicator for dog allergen burden in house dust.",
"     </li>",
"     <li>",
"      Mouse and rat allergens have been detected in the air and surface dust of urban homes. Mus m 1 and Rats n 1 are used as indicator allergens for mouse and rat allergens, respectively, in indoor environments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/14\">",
"       14",
"      </a>",
"      ]. Larger pets, such as goats, geese, chickens, ducks, cows, and horses are typically kept outdoors, but they can produce allergen that can be tracked into the home. Assays are not available for monitoring the presence of these allergens in household surface dust.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881152\">",
"    <span class=\"h3\">",
"     Cockroaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the 50 varieties of cockroach, the German (Blatella germanica) and American (Periplaneta Americana) cockroaches are of particular concern as sources of allergens in homes. Levels of group 1 and 2 German cockroach allergens (Bla g 1 and, Bla g 2) are used as indicator allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/15\">",
"     15",
"    </a>",
"    ]. Potent allergens are released from the saliva, fecal material, secretions, cast skins, and dead bodies of cockroaches. The kitchen, dining room and other areas of the home where food is consumed remain principal locations for cockroach allergen exposure. Reduced exposure to cockroach allergen can be accomplished by confining eating to the kitchen and dining room, putting non-refrigerated items in tightly sealed plastic containers, and removing the garbage on a daily basis. Moreover, frequent vacuuming, damp-mopping of hard floors, and routine cleaning of counter tops and other surfaces reduce potential cockroach allergen exposure. Cockroach allergen exposure is most problematic in urban and tropical areas, in which high densities of cockroaches are maintained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4414985\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR INDOOR AEROALLERGEN ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen sampling can be costly. It is rare for standard air quality assessments performed in work places or other public buildings to assess aeroallergens in a comprehensive way, with the possible exception of mold (because public awareness of mold contamination is high compared to that of other aeroallergens). Typically, if an employee complains of a chronic cough or bad odor confined to an area of the building, an initial evaluation will involve particulate counts, environmental temperature and humidity measurements, and crude mold evaluations.",
"   </p>",
"   <p>",
"    Before any formal sampling and laboratory analysis of dust from an environment is contemplated, the affected individual should initiate a thorough inspection to identify any obvious signs of allergen contamination. Are cat, dog, mouse, or rat droppings evident? Are there dead cockroaches present? Is there high humidity, a musty odor, or visual evidence of water damage? All these signs are readily and inexpensively detected by the individual&rsquo;s eyes or nose. Often times the nose can detect mold contamination that is not visually obvious because it is embedded in the wall.",
"   </p>",
"   <p>",
"    A formal aeroallergen analysis of an environment is most useful for individuals who continue to suffer from allergic or asthmatic symptoms following reasonable efforts at remediation. The analysis can uncover unexpected sources of allergen exposure (eg, epidermal allergen from the pets next door or a rodent or cockroach infestation). Alternatively, it can be useful as formal documentation to counter school or workplace claims of a clean environment when a student or worker continues to experience allergic symptoms. The most common concern in these settings is mold infestation after a water leak.",
"   </p>",
"   <p>",
"    As a general rule, aeroallergen measurements outside of research settings are most likely to be clinically helpful when ALL of the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient spends significant time in the environment",
"     </li>",
"     <li>",
"      The patient has symptoms consistent with IgE-mediated allergic disease (asthma, rhinoconjunctivitis)",
"     </li>",
"     <li>",
"      The patient is sensitized to relevant indoor allergens that can be measured using the techniques available",
"     </li>",
"     <li>",
"      The environment can be altered if a problem is found",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4415385\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL SAMPLING METHODS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881166\">",
"    <span class=\"h2\">",
"     Indoor aeroallergen analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outside of research, indoor aeroallergen analysis is usually performed to evaluate a patient with allergic respiratory symptoms, such as allergic asthma or allergic rhinoconjunctivitis. Homes represent the principal location of most indoor aeroallergen exposure. Work places and schools are generally less problematic since they are constructed in a manner with less carpet and upholstered furniture, which simplifies cleaning. However, early learning and daycare centers where carpet, stuffed toys, bedding, and upholstered furniture are present can be problem areas for allergen exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An initial evaluation often begins often with a &ldquo;global&rdquo; dust specimen that is collected from all the principal living and working areas of the building where the individual spends considerable time and where symptoms are consistently noted. This composite dust specimen represents a survey of the entire space in question, and it can usefully identify the principal source of a gross aeroallergen problem at minimal expense. The collection of a composite sample addresses the concern of allergen heterogeneity among the different rooms in the living space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sampling can be performed by the homeowner using commercially available kits containing specific written guidelines, or by an industrial hygienist. The homeowner who knows where they spend the most time in the environment is often best at collection of a dust specimen in their home when they follow these instructions. Industrial hygienists have some experience but no special certification by any agency in the collection of dust specimens. Dust collectors that fit on the end of a standard household vacuum are available from testing laboratories. If a dust collection kit is purchased directly by the homeowner (online, for example), care should be taken to insure that the kit efficiently collects particles down to 1 micron in size.",
"   </p>",
"   <p>",
"    If the global specimen analysis identifies an allergen source, then evaluation of individual rooms within the environment may be useful. This depends in part on the type of heating and cooling system present. Forced air tends to circulate allergens among all rooms and minimizes the utility of individual room analysis, while baseboard heating systems tend to preserve regional hot spots of allergens near their source.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881173\">",
"    <span class=\"h2\">",
"     Dust specimen processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once collected, the specimen is sent to a laboratory that specializes in environmental allergen testing. Dust specimens can contain debris such as food crumbs, synthetic fibers and soil, hair, plant and insect parts, so the sample is first processed by passing it through a 50 mesh metal sieve (50",
"    <span class=\"nowrap\">",
"     wires/inch,",
"    </span>",
"    each with a 0.009 inch diameter). This allows particles smaller than 250 microns to be collected on a waxed filter paper. Next, 100 milligrams of fine dust are extracted in 2 ml of physiological extraction buffer (phosphate buffered saline containing a carrier protein, such as 1 percent bovine serum albumin). Extraction is rapid, with more than 99 percent of the allergen being solubilized within one hour. However, for convenience, extractions are typically conducted overnight with gentle agitation. In quality laboratories, the extract sterile filtered through a 0.22 micron filter and frozen at -20&ordm;C or lower until analyzed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881180\">",
"    <span class=\"h1\">",
"     LABORATORY ANALYSIS OF ALLERGEN LEVELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain training and expertise are required for a laboratory to provide aeroallergen testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3882441\">",
"    <span class=\"h2\">",
"     Lab certification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians seeking a laboratory to perform aeroallergen analysis can take several steps to insure that the laboratory is able to provide reliable results. A quality laboratory should provide the requested information without reservation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Verify that the laboratory is credentialed by the Federal Clinical Laboratory Improvement Act of 1988 (CLIA-88) by inspection and accreditation by the College of American Pathologists or the American Industrial Hygiene Organization. This certification insures that the director of the laboratory and the technical staff have received the appropriate education and training to perform these tests properly.",
"     </li>",
"     <li>",
"      Request a copy of the procedures for reservoir dust collection, processing, extraction and analysis to insure that the laboratory procedures are logical.",
"     </li>",
"     <li>",
"      Request a copy of two past dust mite, cat, or dog allergen assays and the Levey Jennings Quality Control chart to insure consistency between assay runs for each of the allergens. The purpose of this request is verification that the laboratory has established a system to assess their assay reproducibility over time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3882434\">",
"    <span class=\"h2\">",
"     Assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory should use validated ELISA assays such as two site immunoenzymetric assays or multiplex assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. These assays involve a capture antibody that binds allergen from the extracted surface dust and an enzyme labeled detection antibody that binds to a different epitope on the same allergen molecule. A particle-based multiplex assay has been validated for the simultaneous measurement of multiple dust mites, pet, insect, and rodent epidermal allergens using a small sample volume.",
"   </p>",
"   <p>",
"    Reagents should be verified to be specific for the major allergens in dust mite (eg, Der p 1 and 2, Der f 1 and 2), cat (Fel d 1), dog (Can f 1), cockroach (Bla g 1 and 2), mouse (Mus m 1), and rat (Rat n 1). At the time of this review, Indoor Biotechnology is the primary commercial source for aeroallergen reagents; it provides monoclonal antibodies and qualified allergen standards, and most laboratories which perform aeroallergen testing in the United States purchase reagents from this company.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881187\">",
"    <span class=\"h2\">",
"     Quality control and proficiency testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;No national proficiency testing program exists for monitoring the quality of aeroallergen measurements across clinical laboratories that provide these services. Internal laboratory quality control and inter-laboratory proficiency testing is voluntary. Only one large program called the &ldquo;Healthy Homes Project&rdquo; has instituted a clinical laboratory proficiency testing program in which a common dust is provided to the laboratory periodically and analytical results are monitored over time by participants.",
"   </p>",
"   <p>",
"    Despite the lack of organized oversight, at least one study found that there was acceptable accuracy and precision in a sampling of eight experienced commercial, academic, and municipal laboratories that were measuring dust mite allergens using ELISA-based technologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881194\">",
"    <span class=\"h1\">",
"     TARGET LEVELS OF INDOOR ALLERGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general terms, the lower the level of allergen in the environment, the lower the risk of allergic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/20\">",
"     20",
"    </a>",
"    ]. Complete avoidance of indoor allergens is not achievable in most cases, so studies have attempted to define desirable target levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/21\">",
"     21",
"    </a>",
"    ]. These levels can only estimate tolerable levels for subgroups of patients, since the level that is tolerated by a given individual is obviously dependent upon their sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3882527\">",
"    <span class=\"h2\">",
"     Dust mite allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In limited studies of dust mite sensitive children with asthma, levels &gt;2000 micrograms per gram of surface reservoir dust of indicator allergen (eg, Der p 1, Der p 2, Der f 1, or Der f 2) were associated with increased risk of sensitization, and levels &gt;10,000 micrograms were associated with an increased risk of allergic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/8,20,21\">",
"     8,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3882628\">",
"    <span class=\"h2\">",
"     Cat and dog allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;For both cat (Fel d 1) and dog (Can f 1) allergen, levels &gt;8000 to 10,000 and &gt;80,000 nanograms per gram of fine dust, respectively, in an environment have been identified as targets above which there is an increased risk for allergic sensitization and symptoms, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/8,20,21\">",
"     8,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3882635\">",
"    <span class=\"h2\">",
"     Other allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;No target levels have been identified for indicator allergens of mouse, rat, or cockroach that signify an environment that is a potential problem for an atopic individual who is sensitized to these allergens. Instead, any detectable level of Bla g 1 and Bla g 2 (eg, higher than 1",
"    <span class=\"nowrap\">",
"     Unit/gram)",
"    </span>",
"    is considered indicative of a home that places a sensitized individual at risk for allergic symptoms. Rodent and cockroach exposure can be particularly problematic for children with asthma who live in urban areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33175/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14212424\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergens of clinical importance are identified through an investigative process that begins when a link is made between allergic symptoms and a specific exposure. Suspect substances are collected from the environment, processed in the laboratory to release proteins and other components, and tested with sera from patients to determine what components react with the patients&rsquo; IgE molecules. This same process is repeated whenever a new allergen emerges. (See",
"      <a class=\"local\" href=\"#H6881110\">",
"       'Identification of allergens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Outside of research settings, allergen sampling is most often performed to evaluate indoor spaces, as most people spend the majority of their time indoors, and these environments can be altered if a problem is found, unlike outdoor environments. The principal indoor allergens that induce upper and lower airway allergic symptoms originate from dust mites, fur-bearing pets and rodents, insects (cockroaches), and molds. (See",
"      <a class=\"local\" href=\"#H6881117\">",
"       'Sources of aeroallergens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aeroallergen sampling is likely to be clinically useful only if the patient has allergic rhinitis, rhinoconjunctivitis, or asthma, is known to be sensitized to the allergens included in the assessment, and has persistent symptoms despite already taking reasonable measures to reduce known allergen sources. (See",
"      <a class=\"local\" href=\"#H4414985\">",
"       'Indications for indoor aeroallergen analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aeroallergen sampling is performed on samples of dust from the patient&rsquo;s living space, which is filtered to remove debris and used in a series of ELISA-based assays that detect the major allergens of the important indoor allergens. Specific questions about CLIA accreditation and quality control measures can help clinicians identify appropriate laboratories. (See",
"      <a class=\"local\" href=\"#H4415385\">",
"       'Environmental sampling methods'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6881180\">",
"       'Laboratory analysis of allergen levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Levels of major allergen above which the patient is at increased risk for symptoms have been identified for dust mite, cat, and dog. (See",
"      <a class=\"local\" href=\"#H6881194\">",
"       'Target levels of indoor allergens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/1\">",
"      Spieksma FT, Dieges PH. The history of the finding of the house dust mite. J Allergy Clin Immunol 2004; 113:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/2\">",
"      Hamilton RG. Clinical laboratory assessment of immediate-type hypersensitivity. J Allergy Clin Immunol 2010; 125:S284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/3\">",
"      Morgenstern JP, Griffith IJ, Brauer AW, et al. Amino acid sequence of Fel dI, the major allergen of the domestic cat: protein sequence analysis and cDNA cloning. Proc Natl Acad Sci U S A 1991; 88:9690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/4\">",
"      Weghofer M, Grote M, Resch Y, et al. Identification of Der p 23, a Peritrophin-like Protein, as a New Major Dermatophagoides pteronyssinus Allergen Associated with the Peritrophic Matrix of Mite Fecal Pellets. J Immunol 2013; 190:3059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/5\">",
"      Gr&ouml;nlund H, Saarne T, Gafvelin G, van Hage M. The major cat allergen, Fel d 1, in diagnosis and therapy. Int Arch Allergy Immunol 2010; 151:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/6\">",
"      Ownby DR, Tomlanovich M, Sammons N, McCullough J. Anaphylaxis associated with latex allergy during barium enema examinations. AJR Am J Roentgenol 1991; 156:903.",
"     </a>",
"    </li>",
"    <li>",
"     Pollen count information is available through the website of the American Academy of Allergy, Asthma, and Immunology. www.aaaai.org/nab (Accessed on August 23, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/8\">",
"      Hamilton RG. Assessment of indoor allergen exposure. Curr Allergy Asthma Rep 2005; 5:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/9\">",
"      Hamilton RG, Eggleston PA. Environmental allergen analyses. Methods 1997; 13:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/10\">",
"      Thomas WR, Smith WA, Hales BJ. The allergenic specificities of the house dust mite. Chang Gung Med J 2004; 27:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/11\">",
"      Leitermann K, Ohman JL Jr. Cat allergen 1: Biochemical, antigenic, and allergenic properties. J Allergy Clin Immunol 1984; 74:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/12\">",
"      Bollinger ME, Eggleston PA, Flanagan E, Wood RA. Cat antigen in homes with and without cats may induce allergic symptoms. J Allergy Clin Immunol 1996; 97:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/13\">",
"      de Groot H, Goei KG, van Swieten P, Aalberse RC. Affinity purification of a major and a minor allergen from dog extract: serologic activity of affinity-purified Can f I and of Can f I-depleted extract. J Allergy Clin Immunol 1991; 87:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/14\">",
"      Matsui EC, Simons E, Rand C, et al. Airborne mouse allergen in the homes of inner-city children with asthma. J Allergy Clin Immunol 2005; 115:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/15\">",
"      Arbes SJ Jr, Sever M, Mehta J, et al. Abatement of cockroach allergens (Bla g 1 and Bla g 2) in low-income, urban housing: month 12 continuation results. J Allergy Clin Immunol 2004; 113:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/16\">",
"      Perry TT, Vargas PA, Bufford J, et al. Classroom aeroallergen exposure in Arkansas head start centers. Ann Allergy Asthma Immunol 2008; 100:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/17\">",
"      Luczynska CM, Arruda LK, Platts-Mills TA, et al. A two-site monoclonal antibody ELISA for the quantification of the major Dermatophagoides spp. allergens, Der p I and Der f I. J Immunol Methods 1989; 118:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/18\">",
"      Earle CD, King EM, Tsay A, et al. High-throughput fluorescent multiplex array for indoor allergen exposure assessment. J Allergy Clin Immunol 2007; 119:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/19\">",
"      Pate AD, Hamilton RG, Ashley PJ, et al. Proficiency testing of allergen measurements in residential dust. J Allergy Clin Immunol 2005; 116:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/20\">",
"      Platts-Mills TA, Ward GW Jr, Sporik R, et al. Epidemiology of the relationship between exposure to indoor allergens and asthma. Int Arch Allergy Appl Immunol 1991; 94:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/21\">",
"      Platts-Mills TA, Chapman MD, Pollart SM, et al. Establishing health standards for indoor foreign proteins related to asthma: dust mite, cat and cockroach. Toxicol Ind Health 1990; 6:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33175/abstract/22\">",
"      Sheehan WJ, Rangsithienchai PA, Wood RA, et al. Pest and allergen exposure and abatement in inner-city asthma: a work group report of the American Academy of Allergy, Asthma &amp; Immunology Indoor Allergy/Air Pollution Committee. J Allergy Clin Immunol 2010; 125:575.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13525 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33175=[""].join("\n");
var outline_f32_25_33175=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14212424\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6881103\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6881110\">",
"      IDENTIFICATION OF ALLERGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4414763\">",
"      Determining the importance of an allergen within a population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4414676\">",
"      Identifying the relevance of an allergen to a specific patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3882220\">",
"      Identifying novel allergens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6881117\">",
"      SOURCES OF AEROALLERGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6881124\">",
"      Outdoor aeroallergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6881131\">",
"      Indoor aeroallergens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6881138\">",
"      - Dust mites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6881145\">",
"      - Fur-bearing animals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6881152\">",
"      - Cockroaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4414985\">",
"      INDICATIONS FOR INDOOR AEROALLERGEN ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4415385\">",
"      ENVIRONMENTAL SAMPLING METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6881166\">",
"      Indoor aeroallergen analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6881173\">",
"      Dust specimen processing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6881180\">",
"      LABORATORY ANALYSIS OF ALLERGEN LEVELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3882441\">",
"      Lab certification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3882434\">",
"      Assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6881187\">",
"      Quality control and proficiency testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6881194\">",
"      TARGET LEVELS OF INDOOR ALLERGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3882527\">",
"      Dust mite allergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3882628\">",
"      Cat and dog allergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3882635\">",
"      Other allergens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14212424\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/13525\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13525|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/27/36283\" title=\"table 1\">",
"      Allergen groups",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15127?source=related_link\">",
"      An overview of allergen extracts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/54/11110?source=related_link\">",
"      Assessment of mold in the indoor environment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=related_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40070?source=related_link\">",
"      Latex allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25689?source=related_link\">",
"      The role of fungi (molds) in human disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_25_33176="Organophosphate and carbamate poisoning";
var content_f32_25_33176=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Organophosphate and carbamate poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/25/33176/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33176/contributors\">",
"     Steven Bird, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/25/33176/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33176/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/25/33176/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33176/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/25/33176/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organophosphates and carbamates are potent cholinesterase inhibitors capable of causing severe cholinergic toxicity following cutaneous exposure, inhalation, or ingestion. Although structurally distinct (",
"    <a class=\"graphic graphic_figure graphicRef57527 \" href=\"mobipreview.htm?36/51/37692\">",
"     figure 1",
"    </a>",
"    ), organophosphates and carbamates exhibit similar clinical manifestations with toxicity and require similar management following overdose.",
"   </p>",
"   <p>",
"    An overview of organophosphate and carbamate poisoning will be presented here. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef63540 \" href=\"mobipreview.htm?18/23/18813\">",
"     table 1",
"    </a>",
"    ). A general approach to suspected drug intoxication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12153918\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND SOURCES OF EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organophosphates have been used as insecticides worldwide for more than 50 years. The use of these agents has declined in the last 10 to 20 years, in part due to the development of carbamate insecticides, which are associated with similar toxicities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/1\">",
"     1",
"    </a>",
"    ]. Medical applications of organophosphates and carbamates include reversal of neuromuscular blockade (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    ) and treatment of glaucoma, myasthenia gravis, and Alzheimer disease (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/26/37283?source=see_link\">",
"     echothiophate",
"    </a>",
"    , pyridostigmine, tacrine, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Worldwide, an estimated 3,000,000 people are exposed to organophosphate or carbamate agents each year, with up to 300,000 fatalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the United States, there were more than 8000 reported exposures to these agents in 2008, resulting in fewer than 15 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/4\">",
"     4",
"    </a>",
"    ]. Toxicity generally results from accidental or intentional ingestion of, or exposure to, agricultural pesticides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Other potential causes of organophosphate or carbamate toxicity include ingestion of contaminated fruit, flour, or cooking oil, and wearing contaminated clothing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16823?source=see_link\">",
"     \"Information and educational resources for occupational and environmental health issues in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific agents linked to human poisoning include both carbamate (methomyl and aldicarb) and organophosphate (parathion, fenthion,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    , diazinon, and dursban) insecticides. Chlorpyrifos, the organophosphate agent of dursban, is found in some popular household roach and ant sprays, including Raid&reg; and Black Flag&reg; (",
"    <a class=\"graphic graphic_figure graphicRef74088 \" href=\"mobipreview.htm?9/61/10205\">",
"     figure 2",
"    </a>",
"    ). The United States Environmental Protection Agency (EPA) banned many household uses of chlorpyrifos in 2001, and has restricted its use on certain crops including tomatoes, apples, and grapes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several organophosphorus nerve agents (eg, tabun [GA], sarin [GB], soman [GD]) were developed in Germany during the 1940s, but were not used for military purposes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/8\">",
"     8",
"    </a>",
"    ]. The 1995 sarin attack on the Tokyo subway system by the religious cult Aum Shinrikyo and subsequent international events have heightened awareness regarding the prevention, recognition, and treatment of casualties due to organophosphorus (\"nerve\") agent exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8521?source=see_link\">",
"     \"Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organophosphorus compounds contain carbon and phosphorous acid derivatives (",
"    <a class=\"graphic graphic_figure graphicRef57527 \" href=\"mobipreview.htm?36/51/37692\">",
"     figure 1",
"    </a>",
"    ). These agents are well absorbed through the skin, lungs, and gastrointestinal tract. They bind to acetylcholinesterase (AChE), also known as red blood cell (RBC) acetylcholinesterase, and render this enzyme non-functional. AChE is the enzyme responsible for hydrolysis of acetylcholine to choline and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    , and inhibition leads to an overabundance of acetylcholine at the neuronal synapses and the neuromuscular junction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After some period of time (dependent on the chemical structure of the organophosphorus agent), the acetylcholinesterase-organophosphorus compound undergoes a conformational change, known as \"aging,\" which renders the enzyme",
"    <strong>",
"     irreversibly",
"    </strong>",
"    resistant to reactivation by an antidotal oxime (",
"    <a class=\"graphic graphic_figure graphicRef78828 \" href=\"mobipreview.htm?19/36/20047\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, plasma cholinesterase (also called butylcholinesterase [BuChE] or pseudocholinesterase) and neuropathy target esterase (NTE) are inhibited by organophosphorus agents; however, the clinical significance of these interactions are less certain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carbamate compounds are derived from carbamic acid (",
"    <a class=\"graphic graphic_figure graphicRef57527 \" href=\"mobipreview.htm?36/51/37692\">",
"     figure 1",
"    </a>",
"    ). Like organophosphorus agents, carbamates are rapidly absorbed via all routes of exposure. Unlike organophosphates, these agents are",
"    <strong>",
"     transient",
"    </strong>",
"    cholinesterase inhibitors, which spontaneously hydrolyze from the cholinesterase enzymatic site within 48 hours. Carbamate toxicity tends to be of shorter duration than that caused by equivalent doses of organophosphates, although the mortality rates associated with exposure to these chemical classes are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onset and duration of AChE inhibition varies depending on the organophosphorus agent's rate of AChE inhibition, the route of absorption, enzymatic conversion to active metabolites, and the lipophilicity of the organophosphorus agent. For most agents, oral or respiratory exposures generally result in signs or symptoms within three hours, while symptoms of toxicity from dermal absorption may be delayed up to 12 hours. Lipophilic agents such as dichlofenthion, fenthion, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/21/12627?source=see_link\">",
"     malathion",
"    </a>",
"    are associated with delayed onset of symptoms (up to five days) and prolonged illness (greater than 30 days), which may be related to rapid adipose fat uptake and delayed redistribution from the fat stores (",
"    <a class=\"graphic graphic_table graphicRef63540 \" href=\"mobipreview.htm?18/23/18813\">",
"     table 1",
"    </a>",
"    ). The great variability in toxicity and treatment response among organophosphorus agents, however, is not well understood, leading some to suggest that each agent be considered independently in future studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute toxicity from organophosphorus agents presents with manifestations of cholinergic excess. Primary toxic effects involve the autonomic nervous system, neuromuscular junction, and central nervous system (CNS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/18\">",
"     18",
"    </a>",
"    ]. The parasympathetic nervous system is particularly dependent on acetylcholine regulation, since both the autonomic ganglia and end organs of the parasympathetic nervous system are regulated by nicotinic and muscarinic cholinergic receptor subtypes, respectively (",
"    <a class=\"graphic graphic_figure graphicRef75227 \" href=\"mobipreview.htm?36/57/37790\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The dominant clinical features of acute cholinergic toxicity include bradycardia, miosis, lacrimation, salivation, bronchorrhea, bronchospasm, urination, emesis, and diarrhea. Diaphoresis occurs because sweat glands are regulated through sympathetic activation of postganglionic muscarinic receptors. At times, however, mydriasis and tachycardia may be observed, as sympathetic ganglia also contain nicotinic receptors (",
"    <a class=\"graphic graphic_figure graphicRef75227 \" href=\"mobipreview.htm?36/57/37790\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The muscarinic signs can be remembered by use of one of two mnemonics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       SLUDGE/BBB",
"      </span>",
"      &ndash;",
"      <strong>",
"       S",
"      </strong>",
"      alivation,",
"      <strong>",
"       L",
"      </strong>",
"      acrimation,",
"      <strong>",
"       U",
"      </strong>",
"      rination,",
"      <strong>",
"       D",
"      </strong>",
"      efecation,",
"      <strong>",
"       G",
"      </strong>",
"      astric",
"      <strong>",
"       E",
"      </strong>",
"      mesis,",
"      <strong>",
"       B",
"      </strong>",
"      ronchorrhea,",
"      <strong>",
"       B",
"      </strong>",
"      ronchospasm,",
"      <strong>",
"       B",
"      </strong>",
"      radycardia",
"     </li>",
"     <li>",
"      DUMBELS &ndash;",
"      <strong>",
"       D",
"      </strong>",
"      efecation,",
"      <strong>",
"       U",
"      </strong>",
"      rination,",
"      <strong>",
"       M",
"      </strong>",
"      iosis,",
"      <span class=\"nowrap\">",
"       <strong>",
"        B",
"       </strong>",
"       ronchorrhea/Bronchospasm/Bradycardia,",
"      </span>",
"      <strong>",
"       E",
"      </strong>",
"      mesis,",
"      <strong>",
"       L",
"      </strong>",
"      acrimation,",
"      <strong>",
"       S",
"      </strong>",
"      alivation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted that these mnemonics do",
"    <strong>",
"     NOT",
"    </strong>",
"    take into account the critical CNS and nicotinic effects of these toxins. The nicotinic effects include fasciculations, muscle weakness, and paralysis via acetylcholine stimulation of receptors at the neuromuscular junction. This mechanism is analogous to the depolarizing effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    in producing neuromuscular blockade. Nicotinic and muscarinic receptors also have been identified in the brain, and may contribute to central respiratory depression, lethargy, seizures, and coma (",
"    <a class=\"graphic graphic_figure graphicRef75227 \" href=\"mobipreview.htm?36/57/37790\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cardiac arrhythmias, including heart block and QTc prolongation, are occasionally observed in organophosphorus agent poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/20\">",
"     20",
"    </a>",
"    ]. It is unclear whether these arrhythmias are due to direct toxicity or secondary hypoxemia. In addition, acute pancreatitis may complicate poisoning caused by either organophosphates or carbamates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fatalities from acute organophosphorus agent poisoning generally result from respiratory failure due to a combination of depression of the CNS respiratory center, neuromuscular weakness, excessive respiratory secretions, and bronchoconstriction. Fatalities also occur due to cardiovascular collapse; although the mechanism of this dysfunction is not completely understood, inappropriate vasodilation may play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survivors of acute organophosphorus agent poisoning may have neurobehavioral deficits such as decreased memory, abstraction, and Parkinsonism, which may be permanent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/23\">",
"     23",
"    </a>",
"    ]. It is unclear if these neurocognitive effects are due to direct neurotoxicity of organophosphorus agents themselves, or related to hypoxia and other non-specific effects of serious illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intermediate syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten to 40 percent of patients poisoned with organophosphorus develop a distinct neurologic disorder 24 to 96 hours after exposure. This disorder, referred to as the \"intermediate syndrome,\" consists of characteristic neurological findings including neck flexion weakness, decreased deep tendon reflexes, cranial nerve abnormalities, proximal muscle weakness, and respiratory insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for the development of intermediate syndrome appear to include exposure to a highly fat-soluble organophosphorus agent, and may be related to inadequate doses of oximes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/25\">",
"     25",
"    </a>",
"    ]. The intermediate syndrome has rarely been described following carbamate poisoning.",
"   </p>",
"   <p>",
"    With adequate supportive care, including prolonged mechanical ventilation, most patients have complete resolution of neurologic dysfunction within two to three weeks. Clinical deterioration and improvement appear to correlate with red blood cell (RBC) acetylcholinesterase levels. Nerve conduction studies on patients with intermediate syndrome reveal unique postsynaptic abnormalities that differentiate this disorder from delayed neurotoxicity (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Delayed neurotoxicity'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8712?source=see_link\">",
"     \"Differential diagnosis of peripheral nerve and muscle disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Delayed neurotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organophosphorus agent induced delayed neuropathy (OPIDN) typically occurs one to three weeks after ingestion of one of a small number of specific organophosphorus agents, including chlorpyrifos (",
"    <a class=\"graphic graphic_figure graphicRef66967 \" href=\"mobipreview.htm?8/9/8349\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Carbamates are only rarely associated with the development of OPIDN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The mechanism may involve inhibition of neuropathy target esterase (NTE), rather than alterations in RBC acetylcholinesterase function (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Mechanism of action'",
"    </a>",
"    above)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/31\">",
"     31",
"    </a>",
"    ]. This enzyme, which is found in the brain, peripheral nerves, and lymphocytes, is responsible for the metabolism of various esters within the cell.",
"   </p>",
"   <p>",
"    Affected patients present with transient, painful \"stocking-glove\" paresthesias followed by a symmetrical motor polyneuropathy characterized by flaccid weakness of the lower extremities, which ascends to involve the upper extremities. Sensory disturbances are usually mild. Delayed neurotoxicity primarily affects distal muscle groups, but in severe neurotoxicity, proximal muscles groups may also be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/32\">",
"     32",
"    </a>",
"    ]. Electromyograms and nerve conduction studies of affected patients reveal decreased firing of motor conduction units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/33\">",
"     33",
"    </a>",
"    ]. Histopathologic sections of peripheral nerves reveal Wallerian (or \"dying-back\") degeneration of large distal axons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8712?source=see_link\">",
"     \"Differential diagnosis of peripheral nerve and muscle disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=see_link\">",
"     \"Clinical neurophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of developing OPIDN is",
"    <strong>",
"     independent",
"    </strong>",
"    of the severity of acute cholinergic toxicity. Some organophosphorus agents, such as parathion, are potent cholinergic agents but are not associated with OPIDN. Others, such as triorthocresyl phosphate (TOCP), produce few clinical signs of cholinergic excess but are frequently implicated in OPIDN (",
"    <a class=\"graphic graphic_figure graphicRef66967 \" href=\"mobipreview.htm?8/9/8349\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/35\">",
"     35",
"    </a>",
"    ]. Most cases of mild delayed neurotoxicity improve with time; in severe cases, an upper motor neuron syndrome with spasticity of the lower extremities usually causes permanent disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of organophosphate or carbamate poisoning is made on clinical grounds. In the absence of a known ingestion or exposure, the clinical features of cholinergic excess should indicate the possibility of organophosphate poisoning. Many organophosphorus agents have a characteristic petroleum or garlic-like odor, which may be helpful in establishing the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to significant variability in toxicity, every effort should be made to precisely identify the agent. It is imperative to determine if a dimethyl or a diethyl poison was involved (",
"    <a class=\"graphic graphic_figure graphicRef57527 \" href=\"mobipreview.htm?36/51/37692\">",
"     figure 1",
"    </a>",
"    ). The duration of toxicity and the therapeutic window during which oxime treatment is likely to be effective are markedly different for these two classes of toxins. Dimethyl compounds undergo rapid aging, making early initiation of oxime therapy critical; diethyl compounds may exhibit delayed toxicity, and may require prolonged treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If doubt exists as to whether an organophosphate or carbamate has been ingested, a trial of 1 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    in adults (or 0.01 to 0.02",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in children) may be employed. The absence of signs or symptoms of anticholinergic effects following atropine challenge strongly supports the diagnosis of poisoning with an acetylcholinesterase inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct measurement of RBC acetylcholinesterase (RBC AChE) activity provides a measure of the degree of toxicity. Sequential measurement of RBC AChE activity (if rapidly available) may also be used to determine the effectiveness of oxime therapy in regeneration of the enzyme. Determination of RBC AChE activity can also be helpful in evaluating chronic or occupational exposure. However, most hospital laboratories are unable to perform this test. An assay for plasma (or pseudo-) cholinesterase activity is more easily performed, but does not correlate well with severity of poisoning and should not be used to guide therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Initial resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderately to severely poisoned patients with markedly depressed mental status require 100 percent oxygen and immediate endotracheal intubation. In addition, patients who appear mildly poisoned may rapidly develop respiratory failure due to a combination of CNS respiratory center depression, nicotinic receptor mediated diaphragmatic weakness, bronchospasm, and copious secretions. Thus, patients with mild to moderate poisoning should also be considered for early endotracheal intubation. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef63540 \" href=\"mobipreview.htm?18/23/18813\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinicians should avoid the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    when performing rapid sequence intubation (RSI) in patients with organophosphate (OP) poisoning. Succinylcholine is metabolized by acetylcholinesterase (which is inhibited by OP compounds) leading to exaggerated and prolonged neuromuscular blockade in poisoned patients. Nondepolarizing neuromuscular blocking agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    ) can be used, but may be less effective at standard doses due to competitive inhibition at the neuromuscular junction. Therefore, increased doses will likely be needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bradycardia and hypotension are usually present in moderate to severe poisonings. However, tachycardia or hypotension may transiently occur due to direct sympathetic stimulation. Adequate volume resuscitation with isotonic crystalloid (eg, normal saline or lactated Ringer's solution) should be performed concomitantly with other resuscitative and diagnostic efforts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Atropine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    competes with acetylcholine at muscarinic receptors, preventing cholinergic activation. For moderate to severe cholinergic toxicity, atropine should be administered beginning at a dose of 2 to 5 mg IV for adults and 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV for children. If no effect is noted, the dose should be doubled every three to five minutes until pulmonary muscarinic signs and symptoms are alleviated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    dosing should be titrated to the therapeutic end point of the clearing of respiratory secretions and the cessation of bronchoconstriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/37\">",
"     37",
"    </a>",
"    ]. Tachycardia and mydriasis are",
"    <strong>",
"     NOT",
"    </strong>",
"    appropriate markers for therapeutic improvement, as they may indicate continued hypoxia, hypovolemia, or sympathetic stimulation. In patients with severe poisoning,",
"    <strong>",
"     HUNDREDS",
"    </strong>",
"    of milligrams of atropine by bolus and continuous infusion may be required over the course of several days.",
"   </p>",
"   <p>",
"    This individualized approach to treatment is supported by the results of an open label randomized trial in which patients (n=156) treated with incremental doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    plus infusion experienced lower mortality (6 versus 18 deaths) and fewer episodes of atropine toxicity than patients treated with a standard bolus dose plus infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In June 2003, the United States Food and Drug Administration (FDA) approved pediatric doses of Atropen (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    autoinjector) for children and adolescents exposed to certain nerve agents and pesticides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/39\">",
"     39",
"    </a>",
"    ]. Atropen is designed for acute use by nonphysicians trained in the recognition and treatment of nerve agent or insecticide intoxication. The approved doses for mild symptoms of nerve agent poisoning vary by weight, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      15 to 40 pounds (7 to 18 kg): 0.5 mg",
"     </li>",
"     <li>",
"      &gt;40 to 90 pounds (&gt;19 to 41 kg): 1.0 mg",
"     </li>",
"     <li>",
"      &gt;90 pounds and adults (&gt;41 kg): 2.0",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Up to three times these doses may be administered to children with acute symptoms of severe nerve agent poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pralidoxime",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    does not bind to nicotinic receptors, it is ineffective in treating neuromuscular dysfunction.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/8/16517?source=see_link\">",
"     Pralidoxime",
"    </a>",
"    (2-PAM) and other oximes, such as HI-6 and obidoxime, are cholinesterase reactivating agents that are effective in treating both muscarinic and nicotinic symptoms (",
"    <a class=\"graphic graphic_figure graphicRef78828 \" href=\"mobipreview.htm?19/36/20047\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/3,13,40\">",
"     3,13,40",
"    </a>",
"    ]. Pralidoxime should",
"    <strong>",
"     NOT",
"    </strong>",
"    be administered without concurrent atropine in order to prevent worsening symptoms due to transient oxime-induced acetylcholinesterase inhibition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that oxime therapy be given to all patients with evidence of cholinergic toxicity, patients with neuromuscular dysfunction, or patients with exposures to organophosphorus agents known to cause delayed neurotoxicity (",
"    <a class=\"graphic graphic_figure graphicRef66967 \" href=\"mobipreview.htm?8/9/8349\">",
"     figure 5",
"    </a>",
"    ). The current World Health Organization recommendation for IV bolus therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/8/16517?source=see_link\">",
"     pralidoxime",
"    </a>",
"    is at least 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in adults, and 25 to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for children, based upon the severity of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/14,42\">",
"     14,42",
"    </a>",
"    ]. Although no treatments have been shown to prevent the intermediate syndrome or organophosphorus agent-induced delayed neuropathy (OIDN), early oxime treatment may be of benefit in this situation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/8/16517?source=see_link\">",
"     Pralidoxime",
"    </a>",
"    should be administered slowly over 30 minutes, since rapid administration has occasionally been associated with cardiac arrest, and slow administration prevents the muscle weakness that results from the transient inhibition of acetylcholinesterase as pralidoxime binds to the enzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/44\">",
"     44",
"    </a>",
"    ]. After the bolus dose, it appears that superior antidotal effects occur with pralidoxime given as a continuous infusion of at least 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour in adults and 10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour for children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/42,45\">",
"     42,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe poisonings may result in prolonged redistribution of toxin; therefore, continuous IV therapy should be adjusted based upon the patient's clinical response, and several days of therapy may be required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/46\">",
"     46",
"    </a>",
"    ]. If rapidly available, serial red blood cell acetylcholinesterase (RBC AChE) concentrations may be valuable in determining the efficacy of oxime-induced acetylcholinesterase regeneration.",
"   </p>",
"   <p>",
"    There appears to be great variability among victims of organophosphorus poisoning in their clinical response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/8/16517?source=see_link\">",
"     pralidoxime",
"    </a>",
"    , which is not well understood. In one large, prospective study, patients poisoned with diethyl compounds (eg chlorpyrifos) had significantly lower mortality and intubation rates following treatment with pralidoxime than those poisoned with dimethyl agents (eg dimethoate, fenthion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/17\">",
"     17",
"    </a>",
"    ]. Conversely, in a small, double-blinded randomized trial, no significant benefit, and a trend towards harm, was found in the group treated with pralidoxime compared to patients given placebo, regardless of the type of organophosphate ingested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/47\">",
"     47",
"    </a>",
"    ]. Until this variability is better understood and other treatments become available, we believe that all patients poisoned with organophosphorus agents should be treated with an oxime.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organophosphorus agent-induced seizures should be treated with a benzodiazepine. Prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    has been shown to decrease neurocognitive dysfunction after organophosphorus agent poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. This led, in part, to the US military development of a 10 mg autoinjector of diazepam for use in the setting of chemical attack [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. There is no evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    has any effect on organophosphorus agent-induced seizures, and this agent is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of topical exposure with potential dermal absorption, aggressive decontamination with complete removal of the patient's clothes and vigorous irrigation of the affected areas should be performed. The patient's clothes and belongings should be discarded since they absorb organophosphorus agents, and reexposure may occur even after washing. Health care workers must take precautions to avoid accidental exposure, including providing treatment in a well-ventilated area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/10,52,53\">",
"     10,52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8521?source=see_link\">",
"     \"Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally do not perform gastric lavage. Nevertheless, some clinicians may elect to do so in patients who present less than one hour following ingestion of an organophosphorus agent, AFTER performing endotracheal intubation and initiating therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    and an oxime. Gastric lavage involves substantial risk of aspiration in patients with increased secretions and decreased mental status, and this intervention has never been shown to decrease morbidity or mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following initial resuscitation and treatment, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) be given to patients presenting within one hour of an organophosphorus agent or carbamate ingestion. The standard dose is 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (maximum dose 50 grams). We do not give AC to patients presenting more than one hour following ingestion. Findings from randomized and observational trials suggest that AC given after the first hour provides no benefit to patients with these ingestions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Forced emesis is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    because of the risk of aspiration and seizures. Urinary alkalinization has been suggested, but there is no clear evidence that this intervention improves outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33176/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=see_link\">",
"     \"Enhanced elimination of poisons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p>",
"    Further information on pesticide intoxication can be obtained in the United States from National Pesticide Telecommunications Network at: 1-800-858-7378 or",
"    <a class=\"external\" href=\"file://npic.orst.edu/\">",
"     file://npic.orst.edu/",
"    </a>",
"    (outside the US: 1-806-743-3091).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the diagnosis of organophosphorus agent poisoning is often not subtle, the management of these patients may be complex and protracted. All symptomatic patients should receive therapy with oxygen,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , an oxime (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/8/16517?source=see_link\">",
"     pralidoxime",
"    </a>",
"    ), and a benzodiazepine. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef63540 \" href=\"mobipreview.htm?18/23/18813\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute toxicity from organophosphorus agents presents with manifestations of cholinergic excess. The dominant clinical features of acute cholinergic toxicity include bradycardia, miosis, lacrimation, salivation, bronchorrhea, bronchospasm, urination, emesis, and diarrhea. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Acute toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ten to 40 percent of organophosphorus poisoned patients develop a distinct neurologic disorder 24 to 96 hours after exposure. This disorder consists of characteristic neurological findings including neck flexion weakness, decreased deep tendon reflexes, cranial nerve abnormalities, proximal muscle weakness, and respiratory insufficiency. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Intermediate syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of organophosphate (OP) or carbamate poisoning is made on clinical grounds. In the absence of a known ingestion or exposure, the clinical features of cholinergic excess reflect the possibility of OP poisoning. Due to significant variability in toxicity and treatment, every effort should be made to precisely identify the agent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Moderately to severely poisoned patients with markedly depressed mental status require 100 percent oxygen and immediate tracheal intubation. In addition, patients who appear mildly poisoned may rapidly develop respiratory failure.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       Succinylcholine",
"      </a>",
"      should be avoided when performing rapid sequence intubation in patients with OP poisoning. Bradycardia and hypotension are usually present in moderate to severe poisonings. Adequate volume resuscitation with isotonic crystalloid should be performed concomitantly with other resuscitative and diagnostic efforts. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      therapy for all patients with moderate to severe cholinergic toxicity from OP or carbamate poisoning (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Atropine is started at a dose of 2 to 5 mg IV for adults and 0.05",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV for children. If no effect is noted, the dose is doubled every three to five minutes until pulmonary muscarinic signs and symptoms are alleviated. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Atropine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that oxime therapy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/8/16517?source=see_link\">",
"       pralidoxime",
"      </a>",
"      ) be given to all patients with evidence of cholinergic toxicity, patients with neuromuscular dysfunction, or patients with exposures to organophosphorus agents known to cause delayed neurotoxicity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The current World Health Organization recommendation for IV bolus therapy with pralidoxime is at least 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in adults, and 25 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for children, based on severity of symptoms, administered slowly over 30 minutes. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pralidoxime'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In cases of topical exposure with potential dermal absorption, aggressive decontamination with complete removal of the patient's clothes and vigorous irrigation of the affected areas should be performed. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transfer of moderately to severely ill patients to a regional toxicology treatment center is encouraged.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/1\">",
"      Rotenberg M, Shefi M, Dany S, et al. Differentiation between organophosphate and carbamate poisoning. Clin Chim Acta 1995; 234:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/2\">",
"      Eddleston M, Phillips MR. Self poisoning with pesticides. BMJ 2004; 328:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/3\">",
"      Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev 2003; 22:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/4\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/5\">",
"      Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/6\">",
"      Wu ML, Deng JF, Tsai WJ, et al. Food poisoning due to methamidophos-contaminated vegetables. J Toxicol Clin Toxicol 2001; 39:333.",
"     </a>",
"    </li>",
"    <li>",
"     United States Environmental Protection Agency. Organophosphate pesticide information. www.epa.gov/pesticides/op/chlorpyrifos/consumerqs.htm (Accessed on May 03, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/8\">",
"      Buckley NA, Roberts D, Eddleston M. Overcoming apathy in research on organophosphate poisoning. BMJ 2004; 329:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Recognition of illness associated with exposure to chemical agents--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/10\">",
"      Okudera H, Morita H, Iwashita T, et al. Unexpected nerve gas exposure in the city of Matsumoto: report of rescue activity in the first sarin gas terrorism. Am J Emerg Med 1997; 15:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/11\">",
"      Reutter S. Hazards of chemical weapons release during war: new perspectives. Environ Health Perspect 1999; 107:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/12\">",
"      Tafuri J, Roberts J. Organophosphate poisoning. Ann Emerg Med 1987; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/13\">",
"      Khurana D, Prabhakar S. Organophosphorus intoxication. Arch Neurol 2000; 57:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/14\">",
"      Eddleston M, Szinicz L, Eyer P, Buckley N. Oximes in acute organophosphorus pesticide poisoning: a systematic review of clinical trials. QJM 2002; 95:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/15\">",
"      Morgan JP. The Jamaica ginger paralysis. JAMA 1982; 248:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/16\">",
"      Mutch E, Blain PG, Williams FM. Interindividual variations in enzymes controlling organophosphate toxicity in man. Hum Exp Toxicol 1992; 11:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/17\">",
"      Eddleston M, Eyer P, Worek F, et al. Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study. Lancet 2005; 366:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/18\">",
"      Sidell FR. Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol 1974; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/19\">",
"      Sidell FR. Clinical effects of organophosphorus cholinesterase inhibitors. J Appl Toxicol 1994; 14:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/20\">",
"      Wang MH, Tseng CD, Bair SY. Q-T interval prolongation and pleomorphic ventricular tachyarrhythmia ('Torsade de pointes') in organophosphate poisoning: report of a case. Hum Exp Toxicol 1998; 17:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/21\">",
"      Sahin I, Onbasi K, Sahin H, et al. The prevalence of pancreatitis in organophosphate poisonings. Hum Exp Toxicol 2002; 21:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/22\">",
"      Asari Y, Kamijyo Y, Soma K. Changes in the hemodynamic state of patients with acute lethal organophosphate poisoning. Vet Hum Toxicol 2004; 46:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/23\">",
"      Arima H, Sobue K, So M, et al. Transient and reversible parkinsonism after acute organophosphate poisoning. J Toxicol Clin Toxicol 2003; 41:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/24\">",
"      Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome. N Engl J Med 1987; 316:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/25\">",
"      Groszek B, Pach J, Kys M. Intermediate syndrome in acute fenitrothion poisoning. Przegl Lek 1995; 52:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/26\">",
"      De Bleecker J, Van den Neucker K, Colardyn F. Intermediate syndrome in organophosphorus poisoning: a prospective study. Crit Care Med 1993; 21:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/27\">",
"      Moretto A, Lotti M. Poisoning by organophosphorus insecticides and sensory neuropathy. J Neurol Neurosurg Psychiatry 1998; 64:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/28\">",
"      Sevim S, Aktekin M, Dogu O, et al. Late onset polyneuropathy due to organophosphate (DDVP) intoxication. Can J Neurol Sci 2003; 30:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/29\">",
"      Yang PY, Tsao TC, Lin JL, et al. Carbofuran-induced delayed neuropathy. J Toxicol Clin Toxicol 2000; 38:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/30\">",
"      Dickoff DJ, Gerber O, Turovsky Z. Delayed neurotoxicity after ingestion of carbamate pesticide. Neurology 1987; 37:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/31\">",
"      Glynn P. Neuropathy target esterase. Biochem J 1999; 344 Pt 3:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/32\">",
"      Abou-Donia MB. Organophosphorus ester-induced chronic neurotoxicity. Arch Environ Health 2003; 58:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/33\">",
"      Aygun D, Onar MK, Altintop BL. The clinical and electrophysiological features of a delayed polyneuropathy developing subsequently after acute organophosphate poisoning and it's correlation with the serum acetylcholinesterase. Electromyogr Clin Neurophysiol 2003; 43:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/34\">",
"      Johnson MK. Organophosphorus esters causing delayed neurotoxic effects: mechanism of action and structure activity studies. Arch Toxicol 1975; 34:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/35\">",
"      Craig PH, Barth ML. Evaluation of the hazards of industrial exposure to tricresyl phosphate: a review and interpretation of the literature. J Toxicol Environ Health B Crit Rev 1999; 2:281.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson, MK. Mechanisms of and biomarkers for acute and delayed neuropathic effects of organophosphorus esters. In: Use of Biomarkers in Assessing Health and Environmental Impact of Chemical Pollutants. NATO Advanced Study Workshop. June 1-5, 1992, Amaral-Mendes, J, Traviseds, CC (Eds), Plenum Press, Luso, Portugal 1993. p.169.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/37\">",
"      Eddleston M, Roberts D, Buckley N. Management of severe organophosphorus pesticide poisoning. Crit Care 2002; 6:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/38\">",
"      Abedin MJ, Sayeed AA, Basher A, et al. Open-label randomized clinical trial of atropine bolus injection versus incremental boluses plus infusion for organophosphate poisoning in Bangladesh. J Med Toxicol 2012; 8:108.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration. FDA approves pediatric doses of Atropen. FDA Talk Paper, www.fda.gov/bbs/topics/ANSWERS/2003/ANS01232.html (Accessed on May 03, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/40\">",
"      Newmark J. Therapy for nerve agent poisoning. Arch Neurol 2004; 61:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/41\">",
"      Johnson, MK, Jacobsen, D, Meredith, TJ, et, al. Evaluation of antidotes for poisoning by organophosphorus pesticides. Emerg Med 2000; 12:22.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Environmental Health Criteria No 63. Organophosphorus Pesticides: A General Introduction. World Health Organization, Geneva 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/43\">",
"      Holstege CP, Baer AB. Insecticides. Curr Treat Options Neurol 2004; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/44\">",
"      Schier JG, Hoffman RS. Treatment of sarin exposure. JAMA 2004; 291:182; author reply 182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/45\">",
"      Pawar KS, Bhoite RR, Pillay CP, et al. Continuous pralidoxime infusion versus repeated bolus injection to treat organophosphorus pesticide poisoning: a randomised controlled trial. Lancet 2006; 368:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/46\">",
"      Schexnayder S, James LP, Kearns GL, Farrar HC. The pharmacokinetics of continuous infusion pralidoxime in children with organophosphate poisoning. J Toxicol Clin Toxicol 1998; 36:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/47\">",
"      Eddleston M, Eyer P, Worek F, et al. Pralidoxime in acute organophosphorus insecticide poisoning--a randomised controlled trial. PLoS Med 2009; 6:e1000104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/48\">",
"      McDonough JH Jr, Zoeffel LD, McMonagle J, et al. Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepam in soman-intoxicated guinea pigs. Epilepsy Res 2000; 38:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/49\">",
"      Tuovinen K. Organophosphate-induced convulsions and prevention of neuropathological damages. Toxicology 2004; 196:31.",
"     </a>",
"    </li>",
"    <li>",
"     Office of the U.S. Surgeon General. Army's Diazepam Auto-Injector Package Insert. U.S. Army Medical Research and Development Command (MCMR-RCQ-HR) Fort Detrick, Detrick, MD 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/51\">",
"      Capacio BR, Byers CE, Merk KA, et al. Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. Drug Chem Toxicol 2004; 27:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/52\">",
"      Stacey R, Morfey D, Payne S. Secondary contamination in organophosphate poisoning: analysis of an incident. QJM 2004; 97:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/53\">",
"      Geller RJ, Singleton KL, Tarantino ML, et al. Nosocomial poisoning associated with emergency department treatment of organophosphate toxicity--Georgia, 2000. J Toxicol Clin Toxicol 2001; 39:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/54\">",
"      Eddleston M, Juszczak E, Buckley NA, et al. Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial. Lancet 2008; 371:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33176/abstract/55\">",
"      Roberts D, Buckley NA. Alkalinisation for organophosphorus pesticide poisoning. Cochrane Database Syst Rev 2005; :CD004897.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 339 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33176=[""].join("\n");
var outline_f32_25_33176=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12153918\">",
"      EPIDEMIOLOGY AND SOURCES OF EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intermediate syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Delayed neurotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Initial resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Atropine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pralidoxime",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/339\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/339|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/51/37692\" title=\"figure 1\">",
"      Organophos carbamate structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/61/10205\" title=\"figure 2\">",
"      Chlorpyrifos structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/36/20047\" title=\"figure 3\">",
"      Mechanism organophos pralidox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/57/37790\" title=\"figure 4\">",
"      Nerve toxicity of organophosphates and carbamates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/9/8349\" title=\"figure 5\">",
"      Delayed organophos agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/339|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/23/18813\" title=\"table 1\">",
"      Organophosphate and carbamate poisoning - Rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8521?source=related_link\">",
"      Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8712?source=related_link\">",
"      Differential diagnosis of peripheral nerve and muscle disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16823?source=related_link\">",
"      Information and educational resources for occupational and environmental health issues in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_25_33177="Amyloid light";
var content_f32_25_33177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F63840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F63840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing glomerular amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of glomerular amyloidosis shows nodular amorphous material (arrows) extending from the mesangium into the capillary loops and narrowing or closing the capillary lumens.&nbsp;Amyloid deposits are pale when H&amp;E stain is applied and do not stain with periodic acid-Schiff (PAS) or with methenamine silver stain.&nbsp;They are usually more amorphous than those of diabetic nephropathy, which are positive on PAS and silver stain. The diagnosis of renal amyloidosis relies upon the demonstration of amyloid fibrils by electron microscopy or green birefringence with Congo red staining.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33177=[""].join("\n");
var outline_f32_25_33177=null;
var title_f32_25_33178="Treatment of relapsed or refractory diffuse large B cell lymphoma";
var content_f32_25_33178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapsed or refractory diffuse large B cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/25/33178/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33178/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33178/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/25/33178/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33178/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/25/33178/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/25/33178/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/25/33178/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 30 percent of patients with NHL. It is an aggressive NHL where survival without treatment is measured in months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although significant advances have been made in the treatment of patients with DLBCL, the majority are not cured with conventional therapy. Following relapse, at least 60 percent of patients remain sensitive to conventional treatment, but less than 10 percent of patients experience prolonged disease-free survival with second-line treatment regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of relapsed or refractory DLBCL is discussed here; diagnosis, staging, prognostic measures, and the initial treatment of DLBCL are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oncologic emergencies and treatment-related hematologic toxicities are common in patients with DLBCL. Clinicians must always be alert to their potential presence, and be prepared to deal with them urgently and effectively. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Oncologic emergencies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION FOR RELAPSE OR RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459934356\">",
"    <span class=\"h2\">",
"     Monitoring for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. At these visits, patients are evaluated with a history, physical examination, blood work, and imaging studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link&amp;anchor=H28#H28\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Surveillance for relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459934133\">",
"    <span class=\"h2\">",
"     Defining relapsed and refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory (resistant) DLBCL is defined as a less than 50 percent decrease in lesion size with treatment in the absence of new lesion development. In contrast, progressive disease reflects the appearance of any new lesion, a 50 percent increase in the longest diameter of a previously identified lesion, or",
"    <span class=\"nowrap\">",
"     new/recurrent",
"    </span>",
"    involvement of the bone marrow (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"mobipreview.htm?29/27/30140\">",
"     table 1",
"    </a>",
"    ). Relapsed disease reflects the appearance of any new lesion after attainment of an initial complete remission (CR).",
"   </p>",
"   <p>",
"    Refractory or progressive disease is identified during the post-treatment response evaluation. The majority of relapses occur during the first two years after completion of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/2\">",
"     2",
"    </a>",
"    ]. However, as many as 18 percent of relapses occurs more than five years after initial treatment. Relapses are usually symptomatic and are rarely identified solely on the basis of routine imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Progressive disease or relapse can present with systemic B symptoms (ie, fever, night sweats, weight loss), cytopenias, the development of an extranodal mass, or as the symptomatic or asymptomatic enlargement of the lymph nodes, liver, or spleen.",
"   </p>",
"   <p>",
"    When relapse is suspected, a biopsy of the involved lymph node or mass is recommended to confirm relapse and evaluate for a potential change in histology, for example to an indolent NHL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459934229\">",
"    <span class=\"h2\">",
"     Confirming relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsed DLBCL can be suggested by changes on imaging studies, but can only be confirmed by biopsy. As such, a biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy. In patients with prior complete remission who present with new lymph node or organ involvement, the importance of a repeat biopsy to confirm a diagnosis of recurrent lymphoma cannot be overemphasized. While most of these patients will have recurrent lymphoma, other conditions (eg, tuberculosis, sarcoid, fungal infection, carcinoma) may be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/5\">",
"     5",
"    </a>",
"    ]. Infrequently, patients will have a change in histology, resulting in a change in preferred treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once relapse is confirmed, the patient should undergo a staging evaluation with a physical examination, imaging studies, and a bone marrow biopsy (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"mobipreview.htm?36/59/37819\">",
"     table 2",
"    </a>",
"    ). The pretreatment evaluation of a patient with relapsed disease is similar to that performed prior to initial therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Pretreatment evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACHIEVING A SECOND RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsed or refractory DLBCL is treated with systemic chemotherapy with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    with plans to proceed to high-dose chemotherapy and hematopoietic cell transplantation (HCT) in those with chemotherapy-sensitive disease. The treatment of patients who are not candidates for HCT, who fail to respond to second-line chemotherapy regimens, or who relapse after HCT is generally palliative. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Regimens for patients ineligible for transplant'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the absence of HCT, conventional chemotherapy regimens provide only transient disease control for the majority of patients with relapsed or refractory DLBCL. Patients with primary refractory disease rarely achieve a complete remission when treated with a second chemotherapy regimen. Following relapse from a first complete remission, a subset of patients will achieve a second complete remission with chemotherapy; however, these remissions are generally not durable and long term disease-free survivors are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, approximately half of patients who respond to a second chemotherapy regimen and proceed to HCT will maintain their response at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H68955546\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Numerous studies have illustrated the importance of demonstrating chemotherapy sensitivity prior to proceeding with HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. As an example, a report of 103 patients with refractory or relapsed non-Hodgkin lymphoma, most of whom had DLBCL, evaluated the use of high dose sequential treatment (HST) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    followed by a high-dose regimen and autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/7\">",
"     7",
"    </a>",
"    ]. Of those responding to HST and going on to receive HCT, 53 percent were in continuous complete remission at a median follow-up of two years. In comparison, the two-year overall survival rate of non-responders going on to receive HCT was less than 10 percent; all non-responders to HST who did not receive HCT died of their disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Regimens for transplant candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of chemotherapy agents and combination regimens have been used for patients with resistant or relapsed DLBCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/15-38\">",
"     15-38",
"    </a>",
"    ]. Most of these regimens contain non-cross resistant drugs at higher doses. No agent or regimen has demonstrated superiority to another in this setting. As such, a choice among regimens is largely based upon side effect profiles and clinical experience. In theory, the preferred regimen would exclude agents at dose levels for salvage that the patient has been exposed to recently and would allow for future stem cell collection.",
"   </p>",
"   <p>",
"    The most commonly used regimens are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ICE (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef76030 \" href=\"mobipreview.htm?17/18/17710\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/1,39-44\">",
"       1,39-44",
"      </a>",
"      ] &mdash; Hematologic toxicity is universal with 35 percent of patients requiring transfusion of blood products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/1\">",
"       1",
"      </a>",
"      ]. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      nonhematologic side effects include infection (23 percent) and nephrotoxicity (1 percent). A variation of this regimen (IVE) substitutes",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      for carboplatin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DHAP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/1,17,29\">",
"       1,17,29",
"      </a>",
"      ] &mdash; Hematologic toxicity is universal with 57 percent of patients requiring transfusion of blood products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/1\">",
"       1",
"      </a>",
"      ]. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      nonhematologic side effects include infection (24 percent) and nephrotoxicity (6 percent).",
"     </li>",
"     <li>",
"      ESHAP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/19,46\">",
"       19,46",
"      </a>",
"      ] &mdash; Hematologic toxicity is universal with significant rates of neutropenic fever (30 percent) if growth factors are not used. Other side effects are generally mild and include nausea, vomiting, diarrhea, nephrotoxicity, and electrolyte disturbances.",
"     </li>",
"     <li>",
"      GDP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/47\">",
"       47",
"      </a>",
"      ] &mdash; Hematologic toxicity is universal. Febrile neutropenia is seen in approximately 15 percent of patients.",
"     </li>",
"     <li>",
"      GemOx (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      ) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/48-50\">",
"       48-50",
"      </a>",
"      ] &mdash; Side effects include severe hematologic toxicity in approximately 50 percent of patients and neuropathy, which can be severe. While studies investigating this regimen have been published, oxaliplatin has not been approved by the United States Food and Drug Administration for use in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In phase II studies, response rates for these regimens have ranged from 20 to 85 percent with 26 to 64 percent complete remissions being reported, along with variable degrees of toxicity. Only one randomized trial has compared regimens in this setting. This phase III multicenter randomized trial (the CORAL trial) of 396 patients with DLBCL in first relapse or with primary refractory disease randomly assigned treatment with R-ICE or R-DHAP followed by high dose chemotherapy and autologous hematopoietic cell transplantation (HCT) for responding patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/1\">",
"     1",
"    </a>",
"    ]. The initial therapy included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in 62 percent of patients. Severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    hematologic and nonhematologic toxicity was more common with R-DHAP, especially thrombocytopenia and renal toxicity. At a median follow-up of 27 months, three cycles of R-ICE resulted in similar rates of overall response (64 versus 63 percent), three-year event-free survival (26 and 35 percent), and three-year overall survival (47 and 51 percent) when compared with three cycles of R-DHAP. While, outcomes were inferior for the 17 percent of patients whose tumors harbored an",
"    <span class=\"nowrap\">",
"     8q24/MYC",
"    </span>",
"    rearrangement (eg, four-year overall survival 29 versus 62 percent), a subset analysis did not demonstrate superiority of either treatment regimen in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/51\">",
"     51",
"    </a>",
"    ]. A second randomization showed no benefit when maintenance rituximab was added following HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Maintenance rituximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Any of the regimens listed above would be acceptable second-line chemotherapy. For most patients with relapsed or refractory DLBCL who are candidates for HCT, we suggest the use of ICE chemotherapy rather than another regimen. This preference is largely based upon presumed equal efficacy to other regimens, decreased toxicity when compared with DHAP, and our familiarity with the regimen. The decision to add",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to second-line therapy is largely dependent upon the length of initial response, but is generally encouraged. (See",
"    <a class=\"local\" href=\"#H68956458\">",
"     'Should rituximab be added?'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A chemotherapy regimen is generally administered for two to three cycles. Disease response to therapy is assessed by combined positron emission",
"    <span class=\"nowrap\">",
"     tomography/computed",
"    </span>",
"    tomography scans (or computed tomography alone where PET is not available) three weeks after completion of the second or third chemotherapy cycle. This earlier response assessment (compared with six to eight weeks after initial chemotherapy) allows for responding patients to proceed to transplantation in a timely fashion. A bone marrow biopsy is repeated only if it was abnormal prior to therapy. Patients who demonstrate a partial response or better proceed to hematopoietic cell transplantation (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"mobipreview.htm?29/27/30140\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'High dose chemotherapy and transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An individual&rsquo;s chance of responding to a particular regimen is influenced not only by prior exposure to chemotherapy, but also by other patient- and lymphoma-associated factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The response to salvage therapy is influenced by the length of the prior remission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. As an example, for the 188 patients enrolled in the PARMA trial of autologous HCT, overall response rates to two courses of DHAP were 40 and 69 percent for patients relapsing &lt;12 versus &gt;12 months after the time of initial diagnosis, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exposure to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      as part of induction therapy may decrease the efficacy of rituximab-containing regimens for second-line treatment. As an example, the phase III randomized CORAL trial comparing two rituximab-based regimens both followed by HCT and maintenance rituximab or not in relapsed or refractory DLBCL found that rates of three-year event-free survival were significantly reduced in a subset of patients with prior exposure to rituximab when compared with patients who were rituximab-na&iuml;ve (21 versus 45 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H68956458\">",
"       'Should rituximab be added?'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The International Prognostic Index (IPI) (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"mobipreview.htm?17/21/17757\">",
"       table 4",
"      </a>",
"      ) used to predict outcomes in newly diagnosed DLBCL can also predict outcomes in relapsed disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/1,55\">",
"       1,55",
"      </a>",
"      ]. In the same CORAL trial described above three-year event-free survival rates were lower in patients with an IPI score of 2 to 3 versus 0 to 1 (18 versus 40 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Regimens for patients ineligible for transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent or resistant DLBCL in patients ineligible for transplantation is particularly difficult to treat and is associated with a markedly reduced survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Such patients should be encouraged to participate in a clinical trial, whenever possible. Patients that cannot tolerate the standard chemotherapy regimens described above may be candidates for regimens initially designed for elderly patients. Alternatively, single agent therapy with anthracyclines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , or alkylating agents may be used for palliation of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link&amp;anchor=H1554322491#H1554322491\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Special scenarios'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regimens that have demonstrated activity in this setting include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CEPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      DA-EPOCH (dose-adjusted",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef88411 \" href=\"mobipreview.htm?30/9/30878\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      CEOP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      GDP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      GemOx (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      ) with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/48-50\">",
"       48-50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       Lenalidomide",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/38,63\">",
"       38,63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/64\">",
"       64",
"      </a>",
"      ]&mdash; While initial reports on the use of single agent rituximab for relapsed DLBCL demonstrated response rates of approximately 30 percent, the rate of response among patients who received rituximab as part of their initial treatment regimen is expected to be significantly lower and therefore of limited utility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preferred regimen would exclude agents at dose levels for salvage which the patient has been exposed to recently. Special considerations for the use of chemotherapy in the elderly population are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68956458\">",
"    <span class=\"h2\">",
"     Should rituximab be added?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recombinant anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is a standard component of initial therapy of DLBCL and improves survival rates in this setting. Whether rituximab therapy should be included in the treatment of all patients with relapsed or refractory disease is controversial. This is primarily because the studies that have demonstrated a benefit from rituximab in the setting of relapsed disease have included few patients who received rituximab as part of their initial chemotherapy regimen. Some clinicians choose to include rituximab in the treatment of all patients with relapsed or refractory disease while others reserve the use of rituximab for those patients who relapse late (eg, &gt;6 months) after a complete remission or did not receive rituximab as part of their initial therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 239 patients with relapsed aggressive CD20 positive non-Hodgkin lymphoma (mostly DLBCL) randomly assigned DHAP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      )-based combination chemotherapy with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/65\">",
"       65",
"      </a>",
"      ]. Only 4 percent of patients had received rituximab with induction therapy. Patients with an at least partial remission after two cycles of chemotherapy were eligible for autologous hematopoietic cell transplantation (HCT). The combination of rituximab plus chemotherapy resulted in a significantly higher response rate (75 versus 54 percent) and higher rate of failure-free survival (50 versus 24 percent) at 24 months follow-up.",
"     </li>",
"     <li>",
"      In a report of 202 patients with DLBCL relapsing or progressing after treatment with CHOP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) or CHOP plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , those treated with a rituximab-containing salvage regimen had a significantly better two-year survival than those not receiving rituximab (58 versus 24 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/66\">",
"       66",
"      </a>",
"      ]. The benefit of rituximab was larger among patients who had not received rituximab as part of their initial therapy.",
"     </li>",
"     <li>",
"      A phase III multicenter randomized trial (the CORAL trial) of 396 patients with DLBCL in first relapse or with primary refractory disease randomly assigned treatment with R-ICE (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) or R-DHAP followed by high dose chemotherapy and autologous HCT for responding patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/1\">",
"       1",
"      </a>",
"      ]. The initial therapy included rituximab in 62 percent of patients. When patients were analyzed according to the time of relapse and exposure to rituximab, patients with relapse more than 12 months after diagnosis had similar rates of progression-free survival (PFS) whether or not they had received rituximab previously. In contrast, patients relapsing less than 12 months after diagnosis had inferior PFS if they had received prior rituximab.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is generally well tolerated. A small percentage of patients receiving their first infusion of rituximab will have severe infusion-related hypersensitivity reactions. Rituximab therapy is immunosuppressive and carries a risk of hepatitis B reactivation among patients positive for HBsAg or anti-HBc. The risk of hepatitis B reactivation is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with relapsed DLBCL who did not receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    with initial therapy (which in the current era is exceedingly rare), we recommend the addition of rituximab to second-line chemotherapy rather than the administration of chemotherapy alone. For most patients with relapsed DLBCL who were initially treated with a rituximab-containing regimen, we also suggest the addition of rituximab to second-line chemotherapy rather than the administration of chemotherapy alone. This preference reflects the low rate of side effects with rituximab and the suggestion of an increased response rate that may allow for progression to potentially curable HCT. The evidence supporting the use of rituximab in this setting is strongest for patients relapsing 6 to 12 months after the initial diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HIGH DOSE CHEMOTHERAPY AND TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsed or refractory DLBCL is treated with systemic chemotherapy with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    with plans to proceed to high dose chemotherapy and autologous hematopoietic cell transplantation (HCT) in those with chemotherapy-responsive disease. Allogeneic HCT may be considered for patients with chemotherapy sensitive disease who fail stem cell mobilization or who have bone marrow involvement after second-line chemotherapy.",
"   </p>",
"   <p>",
"    The American Society for Blood and Marrow Transplantation (ASBMT) issued a position statement regarding HCT in DLBCL in 2010, which concluded the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/67\">",
"     67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autologous HCT is recommended as salvage therapy for patients with chemotherapy-sensitive, relapsed DLBCL. (See",
"      <a class=\"local\" href=\"#H68955546\">",
"       'Efficacy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Age is not a contraindication for autologous HCT, although outcomes in older adults are not as good as in younger adults. (See",
"      <a class=\"local\" href=\"#H68955976\">",
"       'Transplantation eligibility'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Peripheral blood is the standard stem cell source for autologous HCT. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Stem cell collection'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Planned tandem or multiple sequential autologous HCT is not recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ASBMT also concluded that there are insufficient data to make recommendations on the routine use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    maintenance after autologous HCT, the ideal number of cycles of induction therapy prior to autologous HCT, the use of allogeneic HCT, and the use of reduced intensity versus myeloablative conditioning regimens for allogeneic HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Maintenance rituximab'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Allogeneic HCT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Autologous HCT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68955976\">",
"    <span class=\"h3\">",
"     Transplantation eligibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eligibility for autologous hematopoietic cell transplantation (HCT) varies across countries and institutions. Age alone should not be a determining factor of transplant eligibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/67\">",
"     67",
"    </a>",
"    ]. Instead, decisions are made on a case-by-case basis based upon \"physiologic age\" and vary across institutions.",
"   </p>",
"   <p>",
"    In most centers in the United States, patients with one or more of the following factors are",
"    <strong>",
"     not",
"    </strong>",
"    considered eligible for autologous HCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct bilirubin &gt;2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (34.2",
"      <span class=\"nowrap\">",
"       &micro;mol/liter)",
"      </span>",
"     </li>",
"     <li>",
"      Serum creatinine &gt;2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (221",
"      <span class=\"nowrap\">",
"       &micro;mol/liter)",
"      </span>",
"      unless on chronic stable dialysis",
"     </li>",
"     <li>",
"      Eastern Cooperative Oncology Group (ECOG) performance status 3 or 4 unless due to bone pain (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      New York Heart Association functional status Class III or IV (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 7",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68955546\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with relapsed or refractory DLBCL that responds to second-line chemotherapy, high dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT) results in superior survival rates than chemotherapy alone. Patients with chemotherapy-sensitive relapse, or who have chemotherapy-sensitive disease but have never achieved complete remission, have a 30 to 60 percent probability of disease-free survival (DFS) at three to five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. In comparison, patients with DLBCL resistant to second-line chemotherapy have a DFS of less than 10 to 20 percent even with autologous HCT.",
"   </p>",
"   <p>",
"    One multicenter randomized trial (the PARMA trial) has compared autologous HCT with consolidation chemotherapy in 215 patients with chemotherapy-sensitive relapsed aggressive NHL (largely DLBCL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/68\">",
"     68",
"    </a>",
"    ]. After an initial two cycles of DHAP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ), the 109 patients (50 percent) with chemotherapy-sensitive disease were randomly assigned to receive either four additional cycles of DHAP or high dose chemotherapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , cytarabine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    ) followed by autologous HCT. After a median follow up in excess of five years, autologous HCT resulted in significantly superior rates of event-free survival (46 versus 12 percent) and overall survival (53 versus 32 percent) (",
"    <a class=\"graphic graphic_figure graphicRef65432 \" href=\"mobipreview.htm?33/8/33933\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The response criteria used in PARMA was based on computed tomography. Positron emission tomography (PET) using 18-fluorodeoxyglucose (FDG) is now a routine way of following disease status and response in lymphoma. Numerous studies have demonstrated that patients with a negative PET scan prior to HCT have higher rates of progression-free and overall survival. Although patients with a positive PET scan do worse than those with a negative PET scan, patients with chemotherapy-sensitive PET-positive disease appear to benefit from HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link&amp;anchor=H17#H17\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Evaluating response to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study examined the impact of FDG-PET scan results before and after transplant on one-year event-free survival and overall survival in 60 patients undergoing autologous HCT for a variety of lymphoma subtypes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/70\">",
"       70",
"      </a>",
"      ]. Patients in this study had achieved at least a partial response by computed tomographic criteria. Results included the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the pre-transplant setting, a positive FDG-PET scan was associated with a significantly lower one-year event-free survival (43 versus 80 percent) and overall survival (53 versus 92 percent).",
"     </li>",
"     <li>",
"      In the post-transplant setting, a positive FDG-PET scan was associated with a significantly lower one-year event-free survival (25 versus 81 percent) and overall survival (50 versus 90 percent).",
"     </li>",
"     <li>",
"      The impact of pre-transplant and post-transplant FDG-PET scan results on post-transplant one-year event-free survival and overall survival did not differ between histologic subtypes of lymphoma (ie, aggressive lymphoma, follicular lymphoma, and Hodgkin lymphoma).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective case series of 39 patients with primary refractory or relapsed DLBCL investigated the predictive value of pre-ASCT PET scans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/71\">",
"       71",
"      </a>",
"      ]. After a median follow-up of three years, patients with a negative PET scan prior to ASCT had the following significant outcomes when compared with those who had a positive PET scan:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Superior progression-free survival at three years (81 versus 35 percent, respectively)",
"     </li>",
"     <li>",
"      Higher rates of three-year overall survival (81 versus 39 percent, respectively)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review and meta-analysis of 12 studies including 630 patients with relapsed lymphoma (313 with DLBCL) examined the predictive value of PET in response assessment performed after salvage chemotherapy and before consolidation high-dose therapy with autologous HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/72\">",
"       72",
"      </a>",
"      ]. A positive PET scan was associated with a significantly shorter progression-free survival (hazard ratio 4.3; 95% CI 3.1 to 6.0).",
"     </li>",
"     <li>",
"      A retrospective analysis of 42 patients with DLBCL undergoing autologous HCT after second-line chemotherapy reported that patients with a positive PET scan after chemotherapy but before HCT who achieved PET negativity after HCT had a similar event-free survival (EFS) rate to those who had a negative PET scan before HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/69\">",
"       69",
"      </a>",
"      ]. In contrast, patients who did not achieve PET negativity after HCT had inferior EFS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who achieve an at least partial response to second-line chemotherapy, we recommend autologous HCT rather than consolidation chemotherapy. Allogeneic HCT may be considered for patients with chemotherapy sensitive disease who fail stem cell mobilization. Patients with disease that does not respond to chemotherapy should be encouraged to enroll on a clinical trial. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Clinical Trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who undergo autologous HCT should be followed longitudinally for relapse and treatment related toxicities. Most relapses occur during the first two years post-HCT and non-relapse mortality surpasses relapse as the main cause of death beginning approximately eight years post-HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/73\">",
"     73",
"    </a>",
"    ]. The most common causes of non-relapse mortality (NRM) in these patients are respiratory failure (31 percent), infection (13 percent), cardiac toxicity (15 percent), and secondary malignancy (15 percent). The most common causes of NRM in the first two years are respiratory failure and infection. After two years, secondary malignancies, including myelodysplastic syndrome, acute leukemia, and solid tumors, are the most common cause of NRM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35530?source=see_link&amp;anchor=H622013943#H622013943\">",
"     \"The approach to hematopoietic cell transplantation survivorship\", section on 'Overview of care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Stem cell collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic stem cells can be harvested directly from the bone marrow or collected by apheresis from the peripheral blood after stimulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF). Peripheral blood progenitor cells (PBPCs) are preferable to bone marrow cells for transplantation due to quicker engraftment and a potential for less contamination of the infused cells with tumor cells. The various sources of hematopoietic stem cells are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link&amp;anchor=H9#H9\">",
"     \"Sources of hematopoietic stem cells\", section on 'Hematopoietic stem cell mobilization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=see_link&amp;anchor=H5#H5\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\", section on 'Autologous PBPC transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PBPCs are cryopreserved in 5 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33123?source=see_link\">",
"     dimethylsulfoxide",
"    </a>",
"    to be thawed just prior to the time of infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/74\">",
"     74",
"    </a>",
"    ]. Infused peripheral blood stem cells or bone marrow may be contaminated by DLBCL cells and may contribute to relapse. It is not possible to determine whether relapse after HCT results from endogenous tumor cells or from tumor cells contaminating the stem cell product (marrow or PBSC). Since most patients relapse in sites of prior bulk disease, reinfused tumor cells may not contribute to relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/75\">",
"     75",
"    </a>",
"    ]; alternatively such cells may selectively localize back to an affected site.",
"   </p>",
"   <p>",
"    The contribution of reinfused lymphoma cells to relapse is supported by gene marker studies as well as studies of minimal residual disease in the stem cell product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 11 patients with DLBCL in first complete remission and with bone marrows negative for malignant cells by polymerase chain reaction (PCR), seven patients still mobilized significant numbers of malignant cells during collection of PBSCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/78\">",
"       78",
"      </a>",
"      ]. Of the five patients who received highly contaminated autologous PBSCs, four relapsed early, three with disseminated lymphoma.",
"     </li>",
"     <li>",
"      In another report, PCR amplification of the bcl-2 rearrangement detected residual lymphoma cells in the purged marrow in 57 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/79\">",
"       79",
"      </a>",
"      ]. Disease free survival (DFS) was significantly better in the patients who had no detectable bcl-2+ cells in the purged marrow, compared with those in whom these cells were detected.",
"     </li>",
"     <li>",
"      Patients in whom lymphoma cells can be cultured from stem cell collections also have a higher risk of relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/80\">",
"       80",
"      </a>",
"      ]. In a study of mafosfamide purging of autologous marrow, patients who received a lower cell dose of CFU-GM, a surrogate marker for more effective ex vivo purging of tumor cells, at the time of transplant had a better event free survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At the present time there is insufficient information to draw any conclusions regarding the effectiveness of tumor cell purging in any type of aggressive lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88183169\">",
"    <span class=\"h3\">",
"     Conditioning regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal conditioning (preparative) regimen prior to HCT is unknown and clinical practice differs by institution according to experience. Myeloablative preparative regimens are used prior to autologous HCT.",
"   </p>",
"   <p>",
"    A myeloablative conditioning regimen consists of a single agent or combination of agents expected to destroy the hematopoietic cells in the bone marrow and produce profound pancytopenia within 1 to 3 weeks from the time of administration. The resulting pancytopenia is long-lasting, usually irreversible, and in most instances fatal, unless hematopoiesis is restored by infusion of hematopoietic stem cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link&amp;anchor=H5#H5\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Myeloablative preparative regimens'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      BCNU,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , cytosine arabinoside and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      (BEAM) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/83\">",
"       83",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       Busulfan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       Melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      , and total body irradiation (TBI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/84\">",
"       84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      (with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) plus TBI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/85\">",
"       85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/20/32071?source=see_link\">",
"       Bendamustine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      (BeEAM) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/86\">",
"       86",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One trial evaluated the use of high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    administered during stem cell mobilization with BEAM chemotherapy, G-CSF, and GM-CSF (one day before chemotherapy; dose 375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    seven days after chemotherapy (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    and one and eight days after HCT (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    in 67 consecutive patients with relapsed aggressive NHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/87\">",
"     87",
"    </a>",
"    ]. At a median follow-up of 20 months, estimated two-year disease-free and overall survivals were 67 and 80 percent, respectively, significantly better than those of a historical control group receiving the same preparative regimen without rituximab (43 and 53 percent, respectively). Infections were not significantly increased in the rituximab-treated group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Maintenance rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recombinant anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is a standard component of initial therapy of DLBCL and is added to second-line chemotherapy regimens for most patients with relapsed or refractory disease. In contrast, maintenance rituximab does not improve outcomes in patients who have undergone autologous hematopoietic cell transplantation (HCT).",
"   </p>",
"   <p>",
"    The phase III multicenter randomized CORAL trial of R-ICE versus R-DHAP in patients with DLBCL in first relapse or with primary refractory disease included a second randomization to maintenance",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every two months for a year) or observation after autologous HCT for the 242 patients with chemotherapy sensitive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/52\">",
"     52",
"    </a>",
"    ]. At a median follow-up of 44 months, when compared with observation, rituximab maintenance resulted in similar rates of event-free survival (52 versus 53 percent), progression-free survival (52 versus 56 percent), and overall survival (61 versus 65 percent) at four years. Treatment with rituximab resulted in more adverse events after day 100, the majority of which were infections. &nbsp;",
"   </p>",
"   <p>",
"    For patients with chemotherapy sensitive disease who undergo autologous HCT, we recommend observation with treatment at the time of relapse rather than the use of maintenance",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . Maintenance rituximab does not improve clinical outcomes in these patients and is associated with increased long-term toxicities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) offers two potential benefits over autologous HCT, namely a tumor-free source of stem cells as well as a possible graft-versus-tumor effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/88\">",
"     88",
"    </a>",
"    ]. Numerous non-controlled studies have investigated its use for patients with relapsed and refractory DLBCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/89-94\">",
"     89-94",
"    </a>",
"    ]. However, allogeneic HCT with a myeloablative chemotherapy regimen is associated with higher transplant-related morbidity and mortality resulting in similar rates of progression-free survival when compared with autologous HCT. Allogeneic HCT may be considered in patients with mobilization failure or relapse following an autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/43/44729?source=see_link\">",
"     \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H459935168\">",
"     'Second relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is only one prospective comparison between allogeneic and autologous approaches for patients with relapsed lymphoma, half of whom had DLBCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/97\">",
"     97",
"    </a>",
"    ]. At two years, progression-free survival for patients receiving allogeneic and autologous HCT was not significantly different at 47 and 24 percent, respectively; recurrence rates were lower in the allogeneic group.",
"   </p>",
"   <p>",
"    Similarly, in a report from the European Bone Marrow Transplantation registry, recurrence rates after allo-HCT were lower than those following autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/89\">",
"     89",
"    </a>",
"    ]. However, there was no overall survival advantage, due to increased transplant-related mortality following allogeneic HCT. Treatment-associated mortality in these studies has ranged from 20 to 50 percent, usually due to complications of graft-versus-host disease (GVHD), opportunistic infection, or pneumonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approaches to improve results of allogeneic HCT, such as non-myeloablative (NMAC) or reduced-intensity conditioning (RIC), and donor lymphocyte infusions are under investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/99-106\">",
"     99-106",
"    </a>",
"    ]. The largest study of conditioning intensity in this setting was a retrospective analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR) of 396 patients with DLBCL who underwent allo-HCT following myeloablative conditioning (MAB, 165 patients), RIC (143 patients), or NMAC (88 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/107\">",
"     107",
"    </a>",
"    ]. The following outcomes were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When compared with those who underwent RIC and NMAC, patients treated with MAB were younger, less likely to have had an autologous HCT, and more likely to have disease that was refractory to treatment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      of advanced stage.",
"     </li>",
"     <li>",
"      Acute and chronic GVHD were seen in approximately 43 and 40 percent, respectively, and were similar following the different conditioning regimens.",
"     </li>",
"     <li>",
"      MAB was associated with higher rates of non-relapse mortality at five years (56 versus 47 and 36 percent), but lower rates of",
"      <span class=\"nowrap\">",
"       relapse/progression",
"      </span>",
"      (26 versus 38 and 40 percent). Estimated rates of progression-free (15 to 25 percent) and overall survival (18 to 26 percent) at five years were similar following the different conditioning regimens.",
"     </li>",
"     <li>",
"      On multivariate analysis, factors that were associated with worse survival included Karnofsky performance score &lt;90 (hazard ratio [HR] 1.48, 95% CI 1.16-1.90) and chemotherapy-resistant relapse (HR 1.70, 95% CI 1.14-2.56). Transplants performed in 2004 or later had better survival (HR 0.60, 95% CI 0.47-0.76).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only a limited number of patients with NHL have undergone syngeneic (identical twin) HCT. The largest published series involved eight patients, seven with aggressive and one with indolent NHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/108\">",
"     108",
"    </a>",
"    ]. All were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and total body irradiation followed by identical twin marrow reinfusion. The majority of patients were in resistant relapse, with one patient in CR at HCT. Seven of the patients achieved CR and four patients were reported to remain in continuous CR from 12 to 126 months after syngeneic HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459935168\">",
"    <span class=\"h1\">",
"     SECOND RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of autologous hematopoietic cell transplant (HCT) recipients experiencing DLBCL relapse is unknown. A third chemotherapy regimen may be administered in an attempt to attain another response. Patients with chemotherapy-sensitive disease may be candidates for an allogeneic HCT, preferably in the context of a clinical trial. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Allogeneic HCT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to chemotherapy for patients with relapse after autologous HCT likely increases the chance of obtaining another response. A retrospective analysis evaluated outcomes in 82 patients with DLBCL relapsing after an autologous HCT whose salvage therapy after HCT included (40 patients) or did not include rituximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/109\">",
"     109",
"    </a>",
"    ]. Patients who received rituximab had significantly higher rates of complete remission (55 versus 21 percent) and overall survival at three years (50 versus 20 percent). A benefit to rituximab therapy was seen both in patients who were rituximab na&iuml;ve and in patients who had previously received rituximab therapy.",
"   </p>",
"   <p>",
"    Patients with chemotherapy-sensitive disease may be candidates for allogeneic HCT. In most centers in the United States, patients are considered eligible for non-myeloablative allogeneic HCT only if they are less than 65 years of age, with normal cardiac, liver, and renal function, and in good performance status (ECOG performance status 0 or 1) (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 6",
"    </a>",
"    ). Eligibility for a conventional myeloablative transplantation is more restrictive in that patients should typically be younger than 55 years of age.",
"   </p>",
"   <p>",
"    Several small studies suggest that non-myeloablative HCT may also be of value in patients with DLBCL relapsing after autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/110-113\">",
"     110-113",
"    </a>",
"    ]. The largest was a retrospective analysis of 101 patients who underwent myeloablative (37 percent) or non-myeloablative (64 percent) allogeneic HCT for the management of DLBCL relapsed after autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/114\">",
"     114",
"    </a>",
"    ]. At a median follow-up of three years, the rates of non-relapse mortality (NRM), relapse, progression-free survival, and overall survival at three years were 28, 30, 42, and 54 percent, respectively. When compared with myeloablative regimens, non-myeloablative preparative regimens were associated with a trend towards less NRM, but higher relapse rates, resulting in similar rates of progression-free and overall survival. NRM was higher in patients 45 years or older and in those who relapsed within 12 months of autologous HCT. Relapse was more common in those with refractory disease at the time of transplant.",
"   </p>",
"   <p>",
"    The following are provided as additional examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis included 48 consecutive patients with relapsed or refractory DLBCL who underwent reduced-intensity allogeneic HCT with an alemtuzumab-containing regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/113\">",
"       113",
"      </a>",
"      ]. Median age was 46 years and patients had received a median of five prior regimens (69 percent had undergone autologous HCT and 17 percent were chemotherapy refractory). At a median follow-up of 52 months, four-year rates of overall survival, progression-free survival, and nonrelapse mortality were 47, 48, and 32 percent, respectively. Rates of grade 2 to 4 acute GVHD and extensive chronic GVHD were 17 and 13 percent, respectively.",
"     </li>",
"     <li>",
"      A second study of non-myeloablative HCT was performed in 20 consecutive patients with aggressive non Hodgkin lymphoma (10 with DLBCL), whose disease had relapsed after autologous HCT, but was still either chemosensitive or stable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/111\">",
"       111",
"      </a>",
"      ]. All patients engrafted. There was one death at 10 months from a fungal infection; a second patient developed disease progression at 115 days, responding to donor lymphocyte infusion. At a median follow-up of 25 months, the estimated three-year progression-free survival was 95 percent.",
"     </li>",
"     <li>",
"      Another case series of non-myeloablative HCT included 31 patients with DLBCL and one patient with Burkitt lymphoma, 75 percent of whom had failed prior autologous HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/112\">",
"       112",
"      </a>",
"      ]. At the time of HCT, patients had attained complete response (44 percent), partial response (28 percent), or had refractory disease (28 percent). After a median follow-up of 45 months, rates of overall and progression-free survival were 45 and 35 percent. For those with chemosensitive disease, rates of three-year overall and progression-free survival were 56 and 43 percent, respectively. Patients with chemotherapy refractory disease did poorly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Areas of active study include novel agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , PI3 kinase inhibitors, and syk inhibitors. The agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , although not approved by regulatory agencies for this indication, has demonstrated activity in this setting when given either alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/25/33178/abstract/38\">",
"     38",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/19/26930?source=see_link\">",
"       \"Patient information: Diffuse large B-cell lymphoma (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/47/2802?source=see_link\">",
"       \"Patient information: Bone marrow transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/60/27588?source=see_link\">",
"       \"Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although significant advances have been made in the treatment of patients with diffuse large B cell lymphoma (DLBCL), the majority are not cured with conventional therapy. Relapsed DLBCL can be suggested by changes on imaging studies but can only be confirmed by biopsy. As such, a biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy. (See",
"      <a class=\"local\" href=\"#H459934229\">",
"       'Confirming relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relapsed or refractory DLBCL is treated with systemic chemotherapy with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      with plans to proceed to high dose chemotherapy and autologous hematopoietic cell transplantation (HCT) in those with chemotherapy-sensitive disease. The treatment of patients who are not candidates for HCT, who fail to respond to second-line chemotherapy regimens, or who relapse after HCT is generally palliative. Enrollment in a well-designed clinical trial should always be encouraged. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical Trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with relapsed or refractory DLBCL who are candidates for HCT, we suggest the use of R-ICE (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) chemotherapy (",
"      <a class=\"graphic graphic_table graphicRef76030 \" href=\"mobipreview.htm?17/18/17710\">",
"       table 3",
"      </a>",
"      ) rather than another regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This preference is largely based upon presumed equal efficacy to other regimens, decreased toxicity when compared with R-DHAP (rituximab,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ), and our familiarity with the regimen. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Regimens for transplant candidates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with relapsed DLBCL who did not receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      with initial therapy, we recommend the addition of rituximab to second-line chemotherapy rather than the administration of chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with relapsed DLBCL who received rituximab with their initial therapy, we suggest the addition of rituximab to second-line chemotherapy rather than the administration of chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H68956458\">",
"       'Should rituximab be added?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who achieve an at least partial response to second-line chemotherapy, we recommend autologous HCT rather than consolidation chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Allogeneic HCT may be considered in patients with mobilization failure or relapse following an autologous HCT. (See",
"      <a class=\"local\" href=\"#H68955546\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/1\">",
"      Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28:4184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/2\">",
"      Larouche JF, Berger F, Chassagne-Cl&eacute;ment C, et al. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol 2010; 28:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/3\">",
"      Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991; 9:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/4\">",
"      Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006; 17:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/5\">",
"      Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007; 110:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/6\">",
"      Singer CR, Goldstone AH. Clinical studies of ABMT in non-Hodgkin's lymphoma. Clin Haematol 1986; 15:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/7\">",
"      Cortelazzo S, Rambaldi A, Rossi A, et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haematol 2001; 114:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/8\">",
"      Freedman AS, Takvorian T, Anderson KC, et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/9\">",
"      Petersen FB, Appelbaum FR, Hill R, et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990; 8:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/10\">",
"      Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/11\">",
"      Phillips GL, Fay JW, Herzig RH, et al. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 1990; 75:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/12\">",
"      Mink SA, Armitage JO. High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma. Oncologist 2001; 6:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/13\">",
"      Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/14\">",
"      Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/15\">",
"      Cabanillas F, Velasquez WS, McLaughlin P, et al. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol 1988; 25:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/16\">",
"      Soiffer RJ, Caligiuri MA, Tondini C, Canellos GP. High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent. Cancer 1989; 64:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/17\">",
"      Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/18\">",
"      Goss PE, Shepherd FA, Scott JG, et al. Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study. Ann Oncol 1991; 2 Suppl 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/19\">",
"      Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/20\">",
"      Chau I, Webb A, Cunningham D, et al. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 115:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/21\">",
"      Avil&eacute;s A, Neri N, Huerta-Guzm&aacute;n J, Fern&aacute;ndez R. Gemcitabine and cisplatin in refractory malignant lymphoma. Oncology 2004; 66:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/22\">",
"      Musolino A, Perrone MA, Michiara M, et al. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. Cancer 2005; 103:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/23\">",
"      Papageorgiou ES, Tsirigotis P, Dimopoulos M, et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. Eur J Haematol 2005; 75:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/24\">",
"      Abali H, Oyan B, Koc Y, et al. IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. Am J Clin Oncol 2005; 28:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/25\">",
"      Todeschini G, Tecchio C, Pasini F, et al. Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897). Cancer 2005; 104:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/26\">",
"      Oki Y, McLaughlin P, Pro B, et al. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer 2005; 104:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/27\">",
"      Woehrer S, Hejna M, Skrabs C, et al. Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma. Oncology 2005; 69:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/28\">",
"      Sor&aacute; F, Piccirillo N, Chiusolo P, et al. Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma. Cancer 2006; 106:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/29\">",
"      Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 2006; 24:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/30\">",
"      Sym SJ, Lee DH, Kang HJ, et al. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2009; 64:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/31\">",
"      Park BB, Kim WS, Eom HS, et al. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. Invest New Drugs 2011; 29:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/32\">",
"      Lignon J, Sibon D, Madelaine I, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/33\">",
"      Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/34\">",
"      Sarris AH, Romaguera J, Hagemeister FB, et al. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma. Oncology (Williston Park) 2001; 15:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/35\">",
"      Sugiyama K, Omachi K, Fujiwara K, et al. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience. Cancer 2002; 94:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/36\">",
"      Younes A, Preti HA, Hagemeister FB, et al. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2001; 12:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/37\">",
"      Rizzieri DA, Sand GJ, McGaughey D, et al. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer 2004; 100:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/38\">",
"      Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:4952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/39\">",
"      Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/40\">",
"      Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103:3684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/41\">",
"      Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000; 96:2399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/42\">",
"      Simpson L, Ansell SM, Colgan JP, et al. Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone. Leuk Lymphoma 2007; 48:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/43\">",
"      Zelenetz AD, Hamlin P, Kewalramani T, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14 Suppl 1:i5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/44\">",
"      Vose J, Sneller V. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. Ann Oncol 2003; 14 Suppl 1:i17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/45\">",
"      Bishton MJ, Lush RJ, Byrne JL, et al. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol 2007; 136:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/46\">",
"      Mart&iacute;n A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008; 93:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/47\">",
"      Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004; 101:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/48\">",
"      L&oacute;pez A, Guti&eacute;rrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 2008; 80:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/49\">",
"      Corazzelli G, Capobianco G, Arcamone M, et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009; 64:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/50\">",
"      El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007; 18:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/51\">",
"      Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012; 119:4619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/52\">",
"      Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30:4462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/53\">",
"      Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/54\">",
"      Vose JM, Weisenburger DD, Loberiza FR, et al. Late relapse in patients with diffuse large B-cell lymphoma. Br J Haematol 2010; 151:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/55\">",
"      Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998; 92:3562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/56\">",
"      Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007; 25:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/57\">",
"      Jabbour E, Chalhoub B, Suzan F, et al. Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure. Leuk Lymphoma 2004; 45:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/58\">",
"      Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood 1990; 76:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/59\">",
"      Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18:3633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/60\">",
"      Jermann M, Jost LM, Taverna Ch, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004; 15:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/61\">",
"      Bartlett NL, Petroni GR, Parker BA, et al. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. Cancer 2001; 92:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/62\">",
"      Moccia A, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): Excellent outcome in diffuse large B cell lymphom afor patients with a contraindication to anthracyclines  (abstract 408). Blood 2009; 114:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/63\">",
"      Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/64\">",
"      Robach E, Ustun C, Kallab A, et al. Rituximab provides durable remission in a patient with refractory aggressive diffuse B-cell lymphoma failing salvage chemotherapy. Leuk Lymphoma 2002; 43:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/65\">",
"      Vellenga E, van Putten WL, van 't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/66\">",
"      Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/67\">",
"      Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011; 17:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/68\">",
"      Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/69\">",
"      Roland V, Bodet-Milin C, Moreau A, et al. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. Bone Marrow Transplant 2011; 46:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/70\">",
"      Filmont JE, Gisselbrecht C, Cuenca X, et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007; 110:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/71\">",
"      Dickinson M, Hoyt R, Roberts AW, et al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol 2010; 150:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/72\">",
"      Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist 2010; 15:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/73\">",
"      Hill BT, Rybicki L, Bolwell BJ, et al. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. Br J Haematol 2011; 152:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/74\">",
"      Berz D, McCormack EM, Winer ES, et al. Cryopreservation of hematopoietic stem cells. Am J Hematol 2007; 82:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/75\">",
"      Blystad AK, Delabie J, Kval&oslash;y S, et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004; 125:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/76\">",
"      Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/77\">",
"      Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83:3068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/78\">",
"      Jacquy C, Sor&eacute;e A, Lambert F, et al. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol 2000; 110:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/79\">",
"      Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325:1525.",
"     </a>",
"    </li>",
"    <li>",
"     Sharp J, Kessinger A, et al. Significance of detection of tumor cells in hematopoetic stem cell harvests of patients with breast cancer. In: Autologous Bone Marrow Transplantation, Dicke V, Armitage K, Dicke-Evinger M (Eds), University of Nebraska Medical Center, Omaha 1991. p.385.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/81\">",
"      Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/82\">",
"      Jacobsen E, Freedman A. B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. Lancet Oncol 2004; 5:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/83\">",
"      Gaspard MH, Maraninchi D, Stoppa AM, et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol 1988; 22:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/84\">",
"      Murata M, Nishida T, Haneda M, et al. A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. Br J Haematol 1999; 105:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/85\">",
"      Bacigalupo A, Vitale V, Corv&ograve; R, et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol 2000; 108:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/86\">",
"      Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118:3419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/87\">",
"      Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/88\">",
"      van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/89\">",
"      Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/90\">",
"      Doocey RT, Toze CL, Connors JM, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005; 131:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/91\">",
"      Long GD, Amylon MD, Stockerl-Goldstein KE, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 1997; 3:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/92\">",
"      Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 20:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/93\">",
"      van Besien K, Thall P, Korbling M, et al. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant 1997; 3:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/94\">",
"      Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/95\">",
"      Freytes CO, Loberiza FR, Rizzo JD, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004; 104:3797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/96\">",
"      Peggs KS, Mackinnon S, Linch DC. The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol 2005; 128:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/97\">",
"      Shipp MA, Abeloff MD, Antman KH, et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 1999; 17:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/98\">",
"      Kim SW, Tanimoto TE, Hirabayashi N, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2006; 108:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/99\">",
"      Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104:3865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/100\">",
"      Khouri IF, Keating M, K&ouml;rbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/101\">",
"      Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/102\">",
"      Nagler A, Slavin S, Varadi G, et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/103\">",
"      Branson K, Chopra R, Kottaridis PD, et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20:4022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/104\">",
"      Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100:4310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/105\">",
"      Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/106\">",
"      Salit RB, Fowler DH, Wilson WH, et al. Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. J Clin Oncol 2012; 30:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/107\">",
"      Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 2012; 120:4256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/108\">",
"      Appelbaum FR, Fefer A, Cheever MA, et al. Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins. Blood 1981; 58:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/109\">",
"      Calvo-Villas JM, Mart&iacute;n A, Conde E, et al. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. Ann Oncol 2010; 21:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/110\">",
"      Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/111\">",
"      Escal&oacute;n MP, Champlin RE, Saliba RM, et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/112\">",
"      Rezvani AR, Norasetthada L, Gooley T, et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/113\">",
"      Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/25/33178/abstract/114\">",
"      van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29:1342.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4708 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33178=[""].join("\n");
var outline_f32_25_33178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION FOR RELAPSE OR RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H459934356\">",
"      Monitoring for relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H459934133\">",
"      Defining relapsed and refractory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H459934229\">",
"      Confirming relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACHIEVING A SECOND RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Regimens for transplant candidates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Regimens for patients ineligible for transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68956458\">",
"      Should rituximab be added?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HIGH DOSE CHEMOTHERAPY AND TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H68955976\">",
"      - Transplantation eligibility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H68955546\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Stem cell collection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88183169\">",
"      - Conditioning regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Maintenance rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459935168\">",
"      SECOND RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4708\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4708|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/8/33933\" title=\"figure 1\">",
"      PARMA trial survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4708|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/27/30140\" title=\"table 1\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/59/37819\" title=\"table 2\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/18/17710\" title=\"table 3\">",
"      R-ICE recipe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17757\" title=\"table 4\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/9/30878\" title=\"table 5\">",
"      daEPOCH-R for non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 6\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 7\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/19/26930?source=related_link\">",
"      Patient information: Diffuse large B-cell lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/60/27588?source=related_link\">",
"      Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35530?source=related_link\">",
"      The approach to hematopoietic cell transplantation survivorship",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_25_33179="Diagnostic criteria for BJHS";
var content_f32_25_33179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Revised diagnostic criteria for the benign joint hypermobility syndrome*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Beighton score of 4/9 or greater",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Arthralgia for more than 3 months in 4 or more joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. A Beighton score of 1, 2 or 3/9 (0 to 3 if over age 50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Arthralgia for 3 months or more in 1-3 joints, or back pain for 3 months or more, of spondylosis, spondylolysis, or spondylolisthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Dislocation or subluxation in more than one joint, or in one joint on more than one&nbsp;occasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Soft tissue rheumatism in 3 or more locations (eg, epicondylitis, tenosynovitis,&nbsp;bursitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Marfanoid habitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Abnormal skin (eg, striae, hyperextensible, thin, or papyraceous scarring)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Eye abnormalities (eg, drooping eyelids, myopia, anti mongoloid slant)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Varicose veins or hernia or uterine/rectal prolapse",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Benign hypermobility syndrome is diagnosed when two major, one major and two minor, or four minor criteria are present. The disorder is excluded in those with Marfan or Ehlers-Danlos syndrome.",
"    </div>",
"    <div class=\"reference\">",
"     From Grahame, R, Bird, HA, Child, A, et al. J Rheumatol 2000; 27:1777.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33179=[""].join("\n");
var outline_f32_25_33179=null;
var title_f32_25_33180="Complement regulatory proteins";
var content_f32_25_33180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complement regulatory proteins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Protein",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Function",
"       </td>",
"       <td class=\"subtitle1\">",
"        Substrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C4bp",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Plasma",
"       </td>",
"       <td>",
"        +DAA*",
"       </td>",
"       <td>",
"        +CA&bull;",
"       </td>",
"       <td>",
"        C4b",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor H",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Plasma",
"       </td>",
"       <td>",
"        +DAA",
"       </td>",
"       <td>",
"        +CA",
"       </td>",
"       <td>",
"        C3b",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DAF",
"       </td>",
"       <td>",
"        Membrane",
"       </td>",
"       <td>",
"        +DAA",
"       </td>",
"       <td>",
"        -CA",
"       </td>",
"       <td>",
"        Convertase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MCP",
"       </td>",
"       <td>",
"        Membrane",
"       </td>",
"       <td>",
"        -DAA",
"       </td>",
"       <td>",
"        +CA",
"       </td>",
"       <td>",
"        C3b/C4b",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CR1",
"       </td>",
"       <td>",
"        Membrane",
"       </td>",
"       <td>",
"        +DAA",
"       </td>",
"       <td>",
"        +CA",
"       </td>",
"       <td>",
"        C3b/C4b",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"space\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C1 inhibitor",
"       </td>",
"       <td>",
"        Plasma",
"       </td>",
"       <td colspan=\"2\">",
"        Inactivates C1",
"       </td>",
"       <td>",
"        C1r/C1s",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S protein",
"       </td>",
"       <td>",
"        Plasma",
"       </td>",
"       <td colspan=\"2\">",
"        Blocks fluid-phase MAC",
"       </td>",
"       <td>",
"        C5b67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD59",
"       </td>",
"       <td>",
"        Membrane",
"       </td>",
"       <td colspan=\"2\">",
"        Blocks MAC on host cells",
"       </td>",
"       <td>",
"        C8/C9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaphylatoxin inactivator",
"       </td>",
"       <td>",
"        Plasma",
"       </td>",
"       <td colspan=\"2\">",
"        Degrades C4a, C3a, C5a",
"       </td>",
"       <td>",
"        C4a/C3a/C5a",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor I",
"       </td>",
"       <td>",
"        Plasma",
"       </td>",
"       <td colspan=\"2\">",
"        Degrades C3b and C4b (requires a cofactor)",
"       </td>",
"       <td>",
"        C3b/C4b",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * DAA is Decay-Accelerating Activity and refers to the ability to dissociate the convertases.",
"     <br>",
"      &bull; CA is Cofactor Activity and indicates participation of the regulator with serine protease factor I to cleave and thereby inactivate C3b and C4b.",
"      <br>",
"       &Delta; C4bp and particularly Factor H transfer from plasma to damaged cells and exposed acellular tissue surfaces (basement membrane) to prevent undesirable complement activation. This is particularly key in cases of extracellular debris accumulation, as in age-related macular degeneration.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33180=[""].join("\n");
var outline_f32_25_33180=null;
var title_f32_25_33181="TPO or c Mpl deficiency";
var content_f32_25_33181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Importance of thrombopoietin (TPO) and its receptor (MPL) in deficient mice",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 327px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Platelet counts in thrombopoietin (TPO) or c-Mpl (MPL, the TPO receptor) homozygous (-/-) or heterozygous (+/-) deficient mice compared with normal (+/+) mice. the platelet count is 10 to 20 percent of normal in homozygous TPO or c-Mpl deficient mice and 65 percent of normal in heterozygous TPO deficient mice.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gurney, AL, Carver-Moore, K, de Sauvage, FJ, et al, Science 1994; 265:1445 and de Sauvage, FJ, Carver-Moore, K, Luoh, SM, et al, J Exp Med 1996; 183:651.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33181=[""].join("\n");
var outline_f32_25_33181=null;
var title_f32_25_33182="Genetic causes parkinsonism";
var content_f32_25_33182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic forms of parkinsonism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        PARK and OMIM designation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene (protein) locus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mode of inheritance and gene alteration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neuropathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Established",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK1",
"        </p>",
"        <p>",
"         MIM 168601",
"        </p>",
"        <p>",
"         <strong>",
"          and",
"         </strong>",
"        </p>",
"        <p>",
"         PARK4",
"        </p>",
"        <p>",
"         MIM 605543",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         SNCA",
"        </p>",
"        <p>",
"         (Alpha-synuclein)",
"        </p>",
"        <p>",
"         4q21",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         AD",
"        </p>",
"        <p>",
"         Missense mutations (PARK1)",
"        </p>",
"        <p>",
"         Whole gene multiplications (PARK4)",
"        </p>",
"       </td>",
"       <td>",
"        Young onset PD with atypical features, dementia with Lewy bodies",
"       </td>",
"       <td>",
"        Nigral degeneration with Lewy bodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK2",
"        </p>",
"        <p>",
"         MIM 602544",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Parkin",
"        </p>",
"        <p>",
"         6q25.2-q27",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         AR",
"        </p>",
"        <p>",
"         Gene dosage alterations and small sequence changes",
"        </p>",
"       </td>",
"       <td>",
"        Young onset PD with dystonia, dyskinesia, sleep benefit, autonomic symptoms",
"       </td>",
"       <td>",
"        Nigral degeneration; most but not all cases lack Lewy bodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK6",
"        </p>",
"        <p>",
"         MIM 605909",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         PINK 1",
"        </p>",
"        <p>",
"         1p35-36",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         AR",
"        </p>",
"        <p>",
"         Small sequence changes, rarely large deletions",
"        </p>",
"       </td>",
"       <td>",
"        Young onset PD",
"       </td>",
"       <td>",
"        Nigral degeneration with Lewy bodies in the brainstem and Meynert nucleus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK7",
"        </p>",
"        <p>",
"         MIM 602533",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         DJ-1",
"        </p>",
"        <p>",
"         1p36",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         AR",
"        </p>",
"        <p>",
"         Point mutations and large deletions",
"        </p>",
"       </td>",
"       <td>",
"        Young onset PD",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK8",
"        </p>",
"        <p>",
"         MIM 607060",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         LRRK2",
"        </p>",
"        <p>",
"         (Dardarin)",
"        </p>",
"        <p>",
"         12q12",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         AD",
"        </p>",
"        <p>",
"         Point mutations",
"        </p>",
"       </td>",
"       <td>",
"        Middle to late onset PD, resembles typical PD, responsive to levodopa",
"       </td>",
"       <td>",
"        Nigral degeneration with variable Lewy body, alpha-synuclein, and tau pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK9",
"        </p>",
"        <p>",
"         MIM 606693",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         ATP13A2",
"        </p>",
"        <p>",
"         1p36",
"        </p>",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Early onset atypical parkinsonism, rapid progression, transient levodopa responsiveness, pyramidal signs, dementia",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        <p>",
"         PARK14",
"        </p>",
"        <p>",
"         MIM 612953",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         PLA2G6",
"        </p>",
"        <p>",
"         22q13.1",
"        </p>",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Adult onset dystonia-parkinsonism",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Tentative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK3",
"        </p>",
"        <p>",
"         MIM 602404",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         ?",
"        </p>",
"        <p>",
"         2p13",
"        </p>",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Onset juvenile to ninth decade, prominent dementia may be present",
"       </td>",
"       <td>",
"        Nigral degeneration with Lewy bodies; plaques and tangles in some",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK5",
"        </p>",
"        <p>",
"         MIM 191342",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         UCHL1",
"        </p>",
"        <p>",
"         4p14",
"        </p>",
"       </td>",
"       <td>",
"        AD?",
"       </td>",
"       <td>",
"        Limited clinical information, relevance to PD unclear",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK10",
"        </p>",
"        <p>",
"         MIM 606852",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         ?",
"        </p>",
"        <p>",
"         Possible susceptibility locus at 1p32",
"        </p>",
"       </td>",
"       <td>",
"        AD?",
"       </td>",
"       <td>",
"        Late onset PD",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK11",
"        </p>",
"        <p>",
"         MIM 607688",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         GIGYF2",
"        </p>",
"        <p>",
"         2q37",
"        </p>",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Relevance to PD unclear",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK12",
"        </p>",
"        <p>",
"         MIM 300557",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         ?",
"        </p>",
"        <p>",
"         Possible susceptibility locus at Xq21-q25",
"        </p>",
"       </td>",
"       <td>",
"        X-linked",
"       </td>",
"       <td>",
"        Late onset PD",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK13",
"        </p>",
"        <p>",
"         MIM 610297",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         HTRA2",
"        </p>",
"        <p>",
"         (Omi/HtrA2)",
"        </p>",
"        <p>",
"         2p12",
"        </p>",
"       </td>",
"       <td>",
"        AD?",
"       </td>",
"       <td>",
"        Relevance to PD unclear",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK15",
"        </p>",
"        <p>",
"         MIM 260300",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         FBXO7",
"        </p>",
"        <p>",
"         22q12-q13",
"        </p>",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Childhood onset, progressive pyramidal tract signs and parkinsonism",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK16",
"        </p>",
"        <p>",
"         MIM 613164",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         PARK16",
"        </p>",
"        <p>",
"         1q32",
"        </p>",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Late onset PD",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         PARK17",
"        </p>",
"        <p>",
"         MIM 614203",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         VPS35",
"        </p>",
"        <p>",
"         16q11.2",
"        </p>",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Late onset PD",
"       </td>",
"       <td>",
"        Nigral degeneration without Lewy bodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Not assigned",
"        </p>",
"        <p>",
"         MIM 603779",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         SNCAIP",
"        </p>",
"        <p>",
"         (Synphilin-1)",
"        </p>",
"        <p>",
"         5q23.1-q23.3",
"        </p>",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Late onset PD",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Not assigned",
"        </p>",
"        <p>",
"         MIM 601828",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         NR4A2",
"        </p>",
"        <p>",
"         (Nurr1)",
"        </p>",
"        <p>",
"         2q22-q23",
"        </p>",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Late onset PD",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Not assigned",
"        </p>",
"        <p>",
"         MIM 174763",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         POLG",
"        </p>",
"        <p>",
"         (DNA polymerase gamma)",
"        </p>",
"        <p>",
"         15q25",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         ?",
"        </p>",
"        <p>",
"         Compound heterozygous mutations",
"        </p>",
"       </td>",
"       <td>",
"        Young onset, atypical parkinsonism, sensory-motor axonal neuropathy",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Not assigned",
"        </p>",
"        <p>",
"         MIM 605558",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         FGF20",
"        </p>",
"        <p>",
"         (Fibroblast growth factor 20)",
"        </p>",
"        <p>",
"         8p22-p21.3",
"        </p>",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Late onset PD",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AD: autosomal dominant; AR: autosomal recessive.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Klein C, Schneider SA, Lang AE. Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to \"PARK\" genes and beyond. Mov Disord 2009; 24:2042.",
"       </li>",
"       <li>",
"        Wider C, Ross OA, Wszolek ZK. Genetics of Parkinson disease and essential tremor. Curr Opin Neurol 2010; 23:388.",
"       </li>",
"       <li>",
"        Shi CH, Tang BS, Wang L, et al. PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort. Neurology 2011; 77:75.",
"       </li>",
"       <li>",
"        Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord 2012; 27:831.",
"       </li>",
"       <li>",
"        <a href=\"file://www.ncbi.nlm.nih.gov/omim\" target=\"_blank\">",
"         Online Mendelian Inheritance in Man",
"        </a>",
"        .",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33182=[""].join("\n");
var outline_f32_25_33182=null;
var title_f32_25_33183="Bone composition and anatomical location";
var content_f32_25_33183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone composition and anatomical location",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Midshaft proximal phalangeal fractures need 6 to 10 weeks and midshaft middle phalangeal fractures require 10 to 14 weeks for complete bony healing. These long healing times are due to the bony composition of the midshaft of the phalanges, which is hard cortical bone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_25_33183=[""].join("\n");
var outline_f32_25_33183=null;
